

# HOSPITAL BASED CANCER REGISTRY

(Partially supported by the National Cancer Registry Programme,  
Indian Council of Medical Research)



## ANNUAL REPORT 2017

**MALABAR CANCER CENTRE**  
THALASSERY, KANNUR DISTRICT, KERALA  
(An autonomous centre under Government of Kerala)



# **MALABAR CANCER CENTRE**

(An Autonomous Centre under Government of Kerala)

Thalassery

## **Hospital Based Cancer Registry Report 2017**

Partially Supported by National Cancer Registry Programme , ICMR

## **ACKNOWLEDGEMENT**

The Hospital Based Cancer Registry of Malabar Cancer Centre expresses its sincere thanks and gratitude to the following Institutions/Departments/Individuals for supporting and promoting the activities of the Registry.

Dr. SatheesanBalasubramanian, Director, Malabar Cancer Centre

National Cancer Registry Programme, Indian Council of Medical Research, Bangalore

Medical Records Division, MCC, Thalassery

Department of Radiation Oncology

Department of Clinical Hematology & Medical Oncology

Department of Pathology

Department of Surgical Oncology

## FROM DIRECTOR'S DESK



**M**alabar Cancer Centre(MCC) is one of the three designated apex cancer centres in the state. Establishment of cancer registry is considered imperative and an essential component for growth and development of a cancer centre. The hospital based cancer registry(HBCR) was set up in MCC after a period of 10 years of its existence. The HBCR was started in 2010 with a medical officer and a junior system analyst after their training in Cancer Institute (WIA) Adyar and NCDIR-NCRP, Bangalore poured in ample and magnanimous support. The registry is supported partly by the NCDIR especially the technical side. Malabar Population Based Cancer Registry was set up in 2014 and it is funded exclusively by the institution. Though it started with northern two districts of Kannur and Kasargode and Mahe of Union territory of Puducherry, it has expanded to include other five districts of northern Kerala.

It with pride and pleasure, the annual report of Hospital Based Cancer Registry for the year 2017 is presented. A total of 4627 malignant cases was reported at MCC during the year 2017. In previous years lung cancer was the leading cancer irrespective of sex, but this year it is noted that breast cancer has taken the lead! Similarly, in contrast to previous reports, the liver cancer and multiple myeloma have emerged

into the list of top ten leading cancers among males and females respectively.

Cancer registries are the fundamental source of objective cancer data and thus are necessary for developing cancer control strategies and related activities. There is a trend towards more hospital based cancer registries being established in Kerala. This will help the Government establishing the Kerala state wide cancer registry in future. Hospital based registries are the back bone of population based registries as it contribute the quality data to the concerned population based registry. I hope the HBCR reports of MCC provides an opportunity to our valuable readers/researchers to learn and probe the disease related and treatment related information. I appreciate the tireless effort of team Cancer Registry & Epidemiology. The leadership of Dr.SainaSunilkumar to nurture the department to the current status is highly laudable and deeply appreciated. The support lent by Dr.Prasanth Mathur ,Director NCDIR ,Bangalore and his team is highly appreciated with gratitude. The backing of the Government would be an understatement had not been mentioned without which the registry would not have been what its today

**Dr. Satheesan Balasubramanian**

DIRECTOR

I am delighted to present our eighth Hospital based cancer registry report for the year 2017. Cancer remains a major research pursuit for our academicians and hope this report will be beneficial. I thank our Director for encouraging and supporting us.

I wish to acknowledge National centre for disease informatics and research, Bengaluru, Director & staff for their continued support & guidance.

Also, I would like to congratulate and thank my entire team involved in putting this report together.

**Dr.Saina Sunilkumar**

Principal investigator  
HBCR-DM Software project  
Malabar cancer centre



## TABLE OF CONTENTS

Sl. No	Contents	Page No
<b>1</b>	<b>Introduction</b>	<b>07</b>
2	Organisation	<b>07</b>
3	Departments & Divisions	<b>09</b>
4	Department of Cancer Registry	<b>11</b>
5	Hospital Based Cancer Registry	<b>11</b>
6	National Cancer Registry Programme	<b>13</b>
7	Patterns of Patient Registration	<b>14</b>
8	Summary of Results	<b>15</b>
9	Leading Site of Cancers	<b>15</b>
10	Tobacco Related Cancers	<b>17</b>
<b>II</b>	<b>Diagnostic, Clinical &amp; Demographic Details</b>	<b>20</b>
<b>III</b>	<b>Detailed Information-NCRP-ICMR</b>	<b>25</b>
<b>IV</b>	<b>Detailed Information-MCC Habits, Systemwise and staging</b>	<b>55</b>
1	New/Old cases	<b>56</b>
2	Systemwise Cancers	<b>56</b>
3	Alcohol Habits & Systemwise Cancer	<b>56</b>
4	Panchewing Habits & Systemwise cancers	<b>56</b>
5	Smoking Habits & Systemwise cancers	<b>57</b>
6	Family History/Hereditary cancers	<b>58</b>
<b>V</b>	<b>Ten Leading Cancers - irrespective of Sex</b>	<b>59</b>
1	Breast	<b>59</b>
2	Lung	<b>62</b>
3	Mouth	<b>65</b>
4	Stomach	<b>68</b>
5	Rectum	<b>71</b>
6	Tongue	<b>74</b>
7	NHL	<b>77</b>
8	Cervix	<b>80</b>
9	Ovary	<b>83</b>
10	Larynx	<b>86</b>
<b>VI</b>	<b>Abbreviations</b>	<b>89</b>
<b>VII</b>	<b>References</b>	<b>89</b>



# INTRODUCTION

Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighboring parts of Karnataka and Tamilnadu states and Union Territory of Pondicherry(Mahe). The centre, situated in a beautiful hill top in Kodiyeri in Thalassery Municipality 5km away from town established in 2001 .The main objective of the Centre is not only to provide comprehensive cancer care but also to develop as a Research and Training Centre of International standards..

The institution is a tertiary cancer centre which renders its service to society with equal thrust on clinical and translational research, Education and Clinical oncological services. MCC is being developed as a postgraduate institute of oncology. The institution is in the process of developing and establishing a unique Clinical Research department to coordinate clinical research activities. It is our immense pleasure to disclose the research association MCC has with School of Health Sciences, Kannur University,

Centre for Electronic Materials Technology, Thrissur and P.S.Vaidhyarathnam Ayurveda College, Kottakkal, HTIC-Chennai, National cancer Grid which are expected to bring in revolutionary changes in the management of cancer. Malabar Cancer Centre has been recognized as Research Institute by Kerala University of Health Science.

The control and management of the Society are vested in the Governing Body consisting of 23 members with the Hon'ble Chief Minister of Kerala as the Chairman, Hon'ble Minister for Health as Vice Chairman and Hon'ble Minister for Power as Alternate Vice-Chairman. The routine activities and functions of the Centre are supervised by the Executive Committee, with the Secretary, Department of Health and Family Welfare, Government of Kerala, being the Chairman of the Committee. The members in the Governing Body and Executive Committee are functioning by virtue of their official positions. The institute has grown to have highly sophisticated facilities to provide cancer care. The hospital has very well trained staff, rendering cancer care to the needy.

# ORGANISATION

**Governing Body (GB):** The Governing Body of the Society consists of 23 members.

1	Chairman	Chief Minister of Kerala
2	Vice-Chairman	Minister for Health & FW, Kerala
3	Alternate Vice-Chairman	Minister for Electricity, Kerala
4	Member	Secretary, Department of Finance, Kerala
5	Member	Secretary, Department of Power, Kerala
6	Member	District Medical Officer, Kannur
7	Member	Secretary, Department of Health & FW, Kerala
8	Member	An eminent Medical Scientist
9	Member	Secretary, Department of Science, Technology & Environment
10	Member	One nominee of the Ministry of Health, Government of India



11	Member	Principal, Medical College, Kozhikode
12	Member	Secretary- Planning & Economic Affairs Department, Kerala
13	Member	Director- Rajiv Gandhi Centre for Bio technology, Trivandrum
14	Member	Director of Medical Education, Directorate of Medical Education, Trivandrum
15	Member & Secretary to GB	Director, Malabar Cancer Centre, Thalassery
16	Member	M.L.A. of the Thalassery constituency
17	Member	President, District Panchayat, Kannur District
18	Member	Chairman, Thalassery Municipality, Thalassery
19	Member	A public man from North Malabar region (to be nominated by Government of Kerala)
20	Member	One Head of the department nominated from Malabar Cancer centre, Thalassery by the Government.
21	Member	One nominee of the Charitable Society established for rehabilitation and financial assistance for poor cancer patients
22	Member	Principal/Chief Executive Officer of Medical College, Pariyaram
23	Member	Director, Regional Cancer Centre, Trivandrum

## EXECUTIVE COMMITTEE

**Executive Committee (EC):** The Executive Committee shall be composed of;

1	Secretary, Health & Family Welfare Department	<b>Chairman</b>
2	Secretary, Finance Department	<b>Member</b>
3	Secretary, Planning and Economic Affairs Department	<b>Member</b>
4	Secretary, Power Department	<b>Member</b>
5	MLA of the Constituency in which MCC is situated	<b>Member</b>
6	Director of Medical Education	<b>Member</b>
7	Chairman, Thalassery Municipality	<b>Member</b>
8	Director, Regional Cancer Centre, Trivandrum	<b>Member</b>
9	Director, Cochin Cancer Centre and Research Centre, Kochi	<b>Member</b>
10	Director, Malabar Cancer Centre	<b>Member/Convenor</b>

## DEPARTMENTS & DIVISION

Sl No	Name of the Department	Divisions under the Department
1.	Department of Radiation Oncology	<ul style="list-style-type: none"> <li>✓ Radiation Oncology Division</li> <li>✓ Radiation Physics Division</li> </ul>
2.	Department of Imageology	<ul style="list-style-type: none"> <li>✓ For administrative purpose, this Department presently will be under Department of Radiation Oncology</li> </ul>
3.	Department of Clinical Hematology and Medical Oncology	<ul style="list-style-type: none"> <li>✓ Clinical Hematology Division</li> <li>✓ Medical Oncology Division</li> <li>✓ Division of Medicine</li> <li>✓ Division of Pediatrics/Pediatric Oncology</li> </ul>
4.	Department of Respiratory Medicine and Critical Care	<ul style="list-style-type: none"> <li>✓ For administrative purpose, this Department presently will be under Department of Clinical Hematology and Medical Oncology</li> </ul>
5.	Department of Surgical Oncology	<ul style="list-style-type: none"> <li>✓ Surgical Oncology Division</li> <li>✓ Division of Rehabilitation Physiotherapy, Speech and Swallowing therapy</li> <li>✓ Division of Gynecology/Gynecologic Oncology</li> <li>✓ Clinical Nutrition and Dietetics</li> </ul>
6.	Department of Clinical Laboratory Services and Translational Research	<ul style="list-style-type: none"> <li>✓ Oncopathology Division</li> <li>✓ Molecular Oncology Division</li> <li>✓ Biochemistry Division</li> <li>✓ Microbiology Division</li> <li>✓ Blood Bank and Transfusion Medicine Division</li> <li>✓ Genetics Division(including Cytogenetics)</li> </ul>

7.	Department of Cancer Registry and Epidemiology	<ul style="list-style-type: none"> <li>✓ Cancer Registry and Epidemiology Division</li> <li>✓ Medical Records Division</li> <li>✓ Health Information Technology Division(Presently under Director)</li> <li>✓ Clinical Research and Biostatistics Division (Presently under Director)</li> </ul>
8.	Department of Community Oncology	<ul style="list-style-type: none"> <li>✓ Community Oncology Division</li> <li>✓ Tobacco Cessation Division</li> </ul>
9.	Department of Onco Anesthesiology	<ul style="list-style-type: none"> <li>✓ Onco Anesthesiology Division</li> </ul>
10.	Department of Cancer Palliative Medicine	<ul style="list-style-type: none"> <li>✓ Psycho-Oncology and Clinical Psychology Division</li> <li>✓ Home Care Services Division.</li> </ul>
11.	Department of Dentistry and Rehabilitation	<ul style="list-style-type: none"> <li>✓ Dentistry and Rehabilitation</li> </ul>
12.	Department of Engineering and Maintenance	<ul style="list-style-type: none"> <li>✓ Engineering &amp; Maintenance</li> </ul>
13.	Department of General Administration	<ul style="list-style-type: none"> <li>✓ General Administration Division</li> <li>✓ Hospital Administration</li> <li>✓ Academic Division &amp; Library and Information Science</li> <li>✓ Public Relations and Clinical Services Division</li> <li>✓ Accounts Division</li> <li>✓ Purchase/Store Division &amp; Pharmacy</li> <li>✓ Human Resources and Establishment Division</li> <li>✓ Security Division</li> </ul>
14.	Department of Oncology Nursing	<ul style="list-style-type: none"> <li>✓ Nursing Services Division</li> </ul>

## DEPARTMENT OF CANCER REGISTRY AND EPIDEMIOLOGY

Department of Cancer Registry and Epidemiology was established in the year 2010 and started Hospital Based Cancer Registry partially supported by National Cancer Registry Programme (ICMR), Bangalore. This is the Seventh Annual report of Hospital Based Cancer Registry of 2016 that is published. Funded project of NCRP/ICMR, Patterns of Care & Survival Studies in Breast, Cervix & Head & Neck cancers started in 2014. Also launched Malabar Population Based Cancer Registry on 1st January 2014 in the districts of Kannur, Kasaragod & Mahe (Two States- Kerala & Pondicherry) with the help of 8 field staffs – 4 social Investigators and 4 Data Collectors. There are three divisions under Department of cancer registry & Epidemiology. The Medical Record division is under the Department of Cancer Registry & Epidemiology.

<b>Cancer Registry Division</b>	
Dr. Saina Sunilkumar	Lecturer, HOD in charge
Smt. Bindu T	Lecturer in Biostatistics
Sri. .Ratheesan.K	Lecturer in Biostatistics
Sri. Prachith K S	Coding Clerk
Sri. Nijin. P	Social Worker
Smt. Sheena.E	Data Entry Operator
Smt. Subina K	Data Entry Operator
Smt. Nisha	Data Entry Operator
<b>Field Staff (Malabar Population Based Cancer Registry)</b>	
Sri. Vineesh A V	Social Investigator
Smt. Haritha Priya	Social Investigator
Sri. Jibin Joseph	Social Investigator
Miss. Rejisha.R	Data Collector
Sri. Muhammed Shafeer C K	Data Collector
Smt. Reshma	Data Collector
<b>EMOR Project</b>	
Sri. Michael Babu N B	Social Investigator
Sreya Dasan R	Data Entry Operator

### **Cancer Registration [HBCR & PBCR]**

Cancer Registration is the process of systematically and continuously collecting information on malignant neoplasm reported. Broadly there are two types of cancer registries – Hospital Based (HBCR) and Population Based (PBCR). Cancer patterns vary not only throughout the world but also between different population Groups within the same country. Epidemiologic studies based on these help in knowing what are happening and what can be done about it. Cancer registries provide the needed information to undertake such investigations.

### **HOSPITAL BASED CANCER REGISTRY**

Hospital based cancer registries collect information of cancers reported in a given hospital, regardless of where that person with cancer resides. Hospital based registries help in assessing cancer patient care in a given hospital and aid in hospital administration including the indi-

vidual hospital's cancer control programmes. Hospital registries help in planning and monitoring survival studies and clinical trials. Hospital registries contribute cases to the population based cancer registry in the area.

The cancer registry is an essential part of any rational Programme of cancer control. Its data can be used in a wide variety of areas of cancer control ranging from etiological research, through primary and secondary prevention to health-care planning and patient care, so benefiting both the individual and society. The main objective of the cancer registry is to collect and classify information on all cancer cases in order to produce statistics on the occurrence of cancer in a defined population and to provide a framework for assessing and controlling the impact of cancer on the community. The collection of information on cancer cases and the production of cancer statistics are only justified, however, if use is made of the data collected. Cancer registry information may be used in a multitude of areas, and the value of the data increases if comparability over time is maintained. Cancer epidemiologists use their knowledge of the distribution of cancer in human populations to search for determinants of the disease.

The primary purpose of Hospital Based Cancer Registries is to contribute to patient care by providing readily accessible information on the patients with cancer, the treatment received and its results. The data is also used for clinical research and for epidemiological purposes. Hospital based cancer registries are concerned with recording of information on the cancer patients seen in a particular hospital (Isabel dos Santos Silva et al, 1999). Within the hospital, a registry is often considered to be an integral part of the hospital's cancer Programme or health care delivery system.

## **FUNCTIONING OF HBCR**

The data abstraction and entry are done using the hospital files. The demographic data are collected and entered into the computer at the time of new patient registration at MCC and transfer to the core- pro forma of the National Cancer Registry Programme (NCRP) of Indian Council of Medical Research (ICMR). The data transfer of the ICMR Core pro forma- first part (demographic details) and second part (diagnostic treatment and follow up details) is entered using the ICMR software after retrieving case sheets from the MCC Medical Records division. All variables in the core pro forma except age and various dates are directly selected. The selection box contains all the codes along with their descriptions for each variable. Hence, this helps to avoid mistakes beyond the range of values for each variable. The selection box corresponding to the variable topography and morphology contains the third edition of international classification of diseases for oncology (ICD-O-3) and the international classification of diseases (ICD-10).

## **DATA PROCESSING ANALYSIS**

After abstraction, coding and data entry the data were sent to the coordinating unit of the NCRP of ICMR, Bangalore in an electronic format and the data was subjected to various range, consistency, unlikely combinations, and duplicate checks. Necessary corrections are done based on the error list of the cases sent by the coordinating unit and this report is generated.

## **ACTIVITIES**

### **Ongoing Projects:**

1. Hospital Based Cancer Registry (HBCR)
2. Population Based Cancer Registry (PBCR)
3. Patterns of Care & Survival Studies
4. Lifestyle and Cancer

# NATIONAL CANCER REGISTRY PROGRAMME


(INDIAN COUNCIL OF MEDICAL RESEARCH)

The Indian Council of Medical Research initiated a network of cancer registries across the country under the National Cancer Registry Programme (NCRP) in December 1981. This move followed the recognition that there was an urgent need for strengthening the existing cancer registries and organization of new cancer registries in different regions of the country.

**The programme was commenced with the following objectives:**

1. To generate reliable data on the magnitude and patterns of cancer – this would be based on morbidity and mortality rates including incidence rates according to gender, age and residence of the patient, anatomical site of cancer and proportion of histological type or microscopic confirmation for each site; pattern of different types of cancer according to relative proportions or ratios in various population sub-groups such as religion, language spoken, educational status; clinical stage of disease when patients come to hospital for treatment and where possible the nature of treatment received and outcome;
2. To undertake epidemiologic studies in the form of case control or cohort studies based on observations of registry data;
3. Provide research base for developing appropriate strategies to aid in National Cancer Control Programme; this would be in the form of planning, monitoring and evaluation of activities under this Programme;
4. Develop human resource in cancer registration and Epidemiology.

## Patterns of Patient Registration



District	Patients	%
Kannur	2404	51.96%
Kasaragod	783	16.92%
Kozhikode	773	16.71%
Malappuram	251	5.42%
Wayanad	248	5.36%
Palakkad	61	1.32%
Thrissur	27	0.58%
Alappuzha	3	0.06%
Kollam	2	0.04%
Pathanamthitta	2	0.04%
Idukki	2	0.04%
Ernakulam	1	0.02%
Thiruvananthapuram	1	0.02%


Other than India	1
------------------	---

Other states	
Pondicherry	30
Karnataka	19
Tamilnadu	9
Rajasthan	3
Assam	1
Uttarakhand	1
Andhra Pradesh	1
West Bengal	1
Assam	1

## SUMMARY OF RESULTS

**Number (#) and proportion (%) according to sex and sex ratio percent**


Male		Female		Sex Ratio	Total
#	%	#	%		
2447	52.9	2180	47.1	112	4627



**Rank, Number(#) and Relative Proportion(%) of Leading Sites of Cancer among Males**


Rank	Sites(ICD 10)	#	%
1	Lung(C33-34)	521	21.3
2	Stomach (C16)	180	7.4
3	Mouth (C03-06)	172	7
4	Tongue(C01-02)	142	5.8
5	NHL(C82-85,C96)	129	5.3
6	Rectum(C19-20)	124	5.1
7	Larynx (C32)	121	4.9
8	Prostate(C61)	107	4.4
9	Oesophagus (C15)	85	3.5
10	Liver (C22)	77	3.1
	All Sites	2447	100





**Rank, Number(#) and Relative Proportion(%) of Leading Sites of Cancer among Females**

Rank	Sites(ICD 10)	#	%
1	Breast (C50)	655	30
2	Cervix Uteri(C53)	157	7.2
3	Ovary(C56)	134	6.1
4	Mouth (C03-06)	110	5
5	Lung (C33-34)	104	4.8
6	Rectum(C19-20)	91	4.2
7	Corpus Uteri(C54)	89	4.1
8	Thyroid(C73)	78	3.6
9	NHL(C82-85,C96)	71	3.3
10	Multiple Myeloma(C90)	69	3.2
	All Sites	2180	100




### Number and Proportions of Cancer by Broad Age Group

Broad Age Groups	Males		Females	
	#	%	#	%
00-14	18	0.7	26	1.2
15-34	71	2.9	100	4.6
35-64	1267	51.8	1372	62.9
65+	1091	44.6	682	31.3
All Sites	2447	100	2180	100

### Tobacco Related Cancers

Number and proportion of cancers associated with use of tobacco relative to all sites of cancer

Males			Females		
All sites	#	%	All sites	#	%
2447	1224	50	2180	356	16.3



**Number (#) and Proportion (%) of Tobacco Related Cancers (TRC) relative to all sites of Cancer**

Site of Cancer	Males		Females	
	#	%	#	%
Lip(C00)	3	0.1	11	0.5
Tongue(C01-02)	142	5.8	57	2.6
Mouth(C03-06)	172	7	110	5
Oropharynx(C10)	64	2.6	4	0.2
Hypopharynx(C12-13)	54	2.2	11	0.5
Pharynx(C14)	2	0.1	-	-
Oesophagus(C15)	85	3.5	40	1.8
Larynx(C32)	121	4.9	5	0.2
Lung(C33-34)	521	21.3	104	4.8
Urinary Bladder(C67)	60	2.5	14	0.6
TRC	1224	50	356	16.3
All Sites	2447	100	2180	100

**Number (#) and Proportion (%) of Specific Sites of Cancers among Tobacco Related Cancers (TRC)**

Site of Cancer	Males		Females	
	#	%	#	%
Lip(C00)	3	0.2	11	3.1
Tongue(C01-02)	142	11.6	57	16
Mouth(C03-06)	172	14.1	110	30.9
Oropharynx(C10)	64	5.2	4	1.1
Hypopharynx(C12-13)	54	4.4	11	3.1
Pharynx(C14)	2	0.2	-	-
Oesophagus(C15)	85	6.9	40	11.2
Larynx(C32)	121	9.9	5	1.4
Lung(C33-34)	521	42.6	104	29.2
Urinary Bladder(C67)	60	4.9	14	3.9
TRC	1224	100	356	100

**Number (#) and Relative Proportion (%) of Tobacco Related Cancers by Five Year Age Groups**

Age Group	Males		Females	
	#	%	#	%
25-29	-	-	1	0.3
30-34	10	0.8	4	1.1
35-39	12	1	8	2.2
40-44	34	2.8	10	2.8
45-49	61	5	18	5.1
50-54	98	8	38	10.7
55-59	175	14.3	35	9.8
60-64	260	21.2	58	16.3
65-69	232	19	66	18.5
70-74	167	13.6	52	14.6
75+	175	14.3	66	18.5
All Ages	1224	100	356	100

**DIAGNOSTIC,  
CLINICAL AND  
DEMOGRAPHIC  
DETAILS**

## DIAGNOSTIC, CLINICAL AND DEMOGRAPHIC DETAILS

Number (#) and relative proportion (%) of cancers by different methods of diagnosis

Method of Diagnosis	Males		Females	
	#	%	#	%
Microscopic	2210	90.3	2077	95.3
All imaging techniques	203	8.3	63	2.9
Clinical	14	0.6	18	0.8
Others	20	0.8	22	1
Total	2447	100	2180	100

Number(#) and Relative Proportion(%) of Cancers based on Different Types of Microscopic Diagnosis

Types of Microscopic Diagnosis	Males		Females	
	#	%	#	%
Histology of Primary	1844	83.4	1763	84.9
Histology of Metastasis	44	2	19	0.9
Cytology of primary	97	4.4	123	5.9
Cytology of Metastasis	93	4.2	40	1.9
Blood Film	51	2.3	43	2.1
Bone Marrow	81	3.7	89	4.3
All Microscopic	2210	100	2077	100

Number (#) and Relative Proportion (%) of Cancer Patients according to Broad Groups of Treatment at Reporting Institution and/or elsewhere

Treatment Groups	Males		Females	
	#	%	#	%
Prior Treatment Only	370	15.1	353	16.2
Prior and Treatment at RI	232	9.5	347	15.9
Treatment only at RI	990	40.5	942	43.2
No Treatment	855	34.9	538	24.7
Total	2447	100	2180	100

**Number (#) and Relative Proportion (%) of Cancer Patients according to Any Specific Treatment relative to all Treatment Procedures (Treatment Only at RI)**

Treatments	Males		Females	
	#	%	#	%
Any Surgery	265	18.8	486	25.6
Any Radiotherapy	668	47.4	564	29.7
Any Chemotherapy	443	31.4	589	31
Any Hormone Therapy	28	2	258	13.6
Any Others	5	0.4	1	0.1
Total	1409	100	1898	100

**Number(#) and Relative Proportion(%) of Type of Treatment(Treatment Only at RI) According to Clinical Extent of Disease - Males**

Clinical Extent-Males								
	Localised		Regional		Distant		Others	
	#	%	#	%	#	%	#	%
Surgery	71	35.1	43	9.7	6	2.2		
Radiotherapy	54	26.7	125	28.3	139	52.1	2	2.5
Chemotherapy	8	4	39	8.8	47	17.6	63	79.7
S+R	19	9.4	54	12.2	3	1.1	1	1.3
S+C	7	3.5	13	2.9	2	0.7		
R+C	26	12.9	122	27.6	57	21.3	10	12.7
S+R+C	4	2	40	9	2	0.7		
Hormonotherapy	5	2.5	3	0.7	8	3		
R + H	7	3.5	2	0.5				
C + H					2	0.7		
R + C + H					1	0.4		
Others	1	0.5	1	0.2			3	3.8
Total Patients	202	100	442	100	267	100	79	100

**Number(#) and Relative Proportion(%) of Type of Treatment(Treatment Only at RI) According to Clinical Extent of Disease – Females**

Clinical Extent-Females								
	Localised		Regional		Distant		Others	
	#	%	#	%	#	%	#	%
Surgery	72	29.9	32	7.2	10	5.3	1	1.5
Radiotherapy	23	9.5	56	12.6	55	29.3	3	4.5
Chemotherapy	5	2.1	36	8.1	32	17	53	79.1
S+R	12	5	22	4.9	1	0.5		
S+C	16	6.6	16	3.6	22	11.7	1	1.5
R+C	32	13.3	71	15.9	31	16.5	8	11.9
S+R+C	13	5.4	60	13.5				
Hormonotherapy	1	0.4	8	1.8	8	4.3		
S + H	14	5.8	9	2				
R + H			2	0.4	9	4.8		
C + H			2	0	11	5.9		
S+R+H	4	1.7	9	2	1	0.5		
S+C+H	19	7.9	9	2				
R + C + H			4	0.9	5	2.7		
S+R+C+H	30	12.4	110	24.7	3	1.6		
Others							1	1.5
Total Patients	241	100	446	100	188	100	67	100





**DETAILED INFORMATION  
NCRP-ICMR  
DIAGNOSTIC, CLINICAL  
AND DEMOGRAPHIC**

**Table 1(a): Number of Cancers by Site (ICD-10) and Five Year Age Group – Males**

As on: 26/06/2020

ICD 10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unk	Total	%
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-	2	1	-	-	-	3	0.1
C01-02	Tongue	-	-	-	-	-	-	6	5	11	19	18	20	19	18	15	11	-	142	5.8
C03-06	Mouth	-	-	-	-	-	-	4	5	11	16	11	18	30	29	24	24	-	172	7.0
C07-08	Salivary Gland	-	-	-	-	-	-	-	-	2	1	-	-	1	-	-	3	-	7	0.3
C09	Tonsil	-	-	-	-	-	-	-	-	-	2	2	1	4	1	-	2	-	12	0.5
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	2	1	5	10	20	10	9	7	-	64	2.6
C11	Nasopharynx	-	-	-	1	-	-	-	1	-	2	-	1	3	4	1	-	-	13	0.5
C12-13	Hypopharynx	-	-	-	-	-	-	-	-	-	3	2	6	15	12	7	9	-	54	2.2
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	2	0.1
C15	Oesophagus	-	-	-	-	-	-	-	-	1	1	7	17	18	15	9	17	-	85	3.5
C16	Stomach	-	-	-	-	-	-	2	1	5	11	14	25	37	37	26	22	-	180	7.4
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	1	2	1	1	-	1	-	6	0.2
C18	Colon	-	-	-	-	-	1	1	3	4	4	8	4	14	8	9	9	-	65	2.7
C19-20	Rectum	-	-	-	-	-	1	-	4	4	10	12	17	22	19	22	13	-	124	5.1
C21	Anus & Anal Canal	-	-	-	-	-	-	1	-	-	1	-	2	-	1	1	3	-	9	0.4
C22	Liver	-	-	-	-	-	-	-	-	4	5	5	13	18	14	15	3	-	77	3.1
C23-24	Gallbladder etc.	-	-	-	-	-	-	-	1	1	4	-	2	3	1	3	-	-	15	0.6
C25	Pancreas	-	-	-	-	-	-	-	1	3	5	6	6	4	9	6	3	-	43	1.8
C30-31	Nose, Sinuses etc.	-	-	-	-	-	-	-	-	1	2	2	1	1	2	-	-	-	9	0.4
C32	Larynx	-	-	-	-	-	-	-	-	3	6	12	25	29	16	13	17	-	121	4.9
C33-34	Lung etc.	-	-	-	-	-	-	-	1	6	13	41	69	123	115	80	73	-	521	21.3
C37-38	Other Thoracic Organs	-	-	-	-	1	-	-	-	1	-	-	-	-	-	-	-	-	2	0.1
C40-41	Bone	-	-	3	2	1	-	-	2	-	-	1	3	-	-	1	1	-	14	0.6
C43	Melanoma of Skin	-	-	-	-	1	-	-	-	2	1	3	7	3	14	4	6	-	41	1.7
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	1	0.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	-	-	1	2	-	4	4	-	-	3	-	1	3	5	1	1	-	25	1.0
C50	Breast	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-	2	0.1
C60	Penis	-	-	-	-	-	-	-	-	2	-	2	-	3	-	-	2	-	9	0.4
C61	Prostate	-	-	-	-	-	-	-	-	-	-	6	11	14	27	26	23	-	107	4.4
C62	Testis	-	-	-	1	-	1	3	2	-	-	-	-	1	-	-	-	-	8	0.3
C63	Other Male Genital	-	-	-	-	-	-	-	-	2	-	-	-	-	-	-	-	-	2	0.1
C64	Kidney etc.	-	-	-	-	-	-	-	1	2	3	4	7	4	3	3	2	-	29	1.2
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	0.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	-	-	-	-	-	-	-	1	-	2	2	10	4	15	9	17	-	60	2.5
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1	0.0
C70-72	Brain, Nervous System	-	-	-	-	1	3	4	5	5	6	2	2	4	5	1	2	-	40	1.6
C73	Thyroid	-	-	-	-	-	-	-	1	2	5	5	2	1	1	4	-	-	21	0.9
C74	Adrenal Gland	-	-	-	-	-	-	-	-	1	-	-	-	1	-	-	-	-	2	0.1
C81	Hodgkins Disease	-	3	1	1	-	2	1	3	1	-	1	3	2	2	-	-	-	20	0.8
C82-85,C96	NHL	1	-	2	1	-	6	3	6	7	8	12	14	18	20	14	17	-	129	5.3
C88	Maliq Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	2	0.1
C90	Multiple Myeloma	-	-	-	-	-	-	-	1	-	3	5	13	5	6	12	3	-	48	2.0
C91	Lymphoid Leuk.	1	1	1	2	2	1	1	1	2	-	1	1	2	4	-	-	-	20	0.8
C92-94	Myeloid Leukaemia	3	-	1	-	-	2	3	4	7	3	7	6	6	5	6	6	-	59	2.4
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	-	-	-	-	1	-	-	-	2	3	7	6	14	14	14	19	-	80	3.3
	<b>All Sites</b>	<b>5</b>	<b>4</b>	<b>9</b>	<b>10</b>	<b>7</b>	<b>21</b>	<b>33</b>	<b>49</b>	<b>94</b>	<b>143</b>	<b>205</b>	<b>325</b>	<b>451</b>	<b>437</b>	<b>337</b>	<b>317</b>	<b>-</b>	<b>2447</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 1(b): Number of Cancers by Site (ICD-10) and Five Year Age Group - Females**

As on: 26/06/2020

ICD 10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unk	Total	%
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-	2	2	2	5	-	11	0.5
C01-02	Tongue	-	-	-	-	-	-	1	3	5	4	6	4	11	10	7	6	-	57	2.6
C03-06	Mouth	-	-	-	-	-	-	-	2	2	4	7	8	16	20	17	34	-	110	5.0
C07-08	Salivary Gland	-	1	1	-	-	1	-	1	-	3	3	-	1	1	1	2	-	15	0.7
C09	Tonsil	-	-	-	-	-	-	-	-	-	1	-	-	-	2	-	-	-	3	0.1
C10	Oth. Oropharynx	-	-	-	-	-	-	-	1	-	-	-	-	1	1	-	1	-	4	0.2
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	1	2	1	-	-	-	4	0.2
C12-13	Hypopharynx	-	-	-	-	-	-	-	-	-	1	2	1	2	2	3	-	-	11	0.5
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	-	-	-	-	-	-	-	1	1	1	4	4	4	9	9	7	-	40	1.8
C16	Stomach	-	-	-	-	-	1	1	4	5	7	4	6	6	5	8	17	-	64	2.9
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1	0.0
C18	Colon	-	-	-	-	1	-	1	4	8	5	6	9	6	5	3	5	-	53	2.4
C19-20	Rectum	-	-	-	-	1	1	4	4	4	8	7	11	15	17	7	12	-	91	4.2
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	1	-	3	0.1
C22	Liver	1	-	-	-	-	1	-	2	4	1	3	6	-	2	2	-	-	22	1.0
C23-24	Gallbladder etc.	-	-	-	-	-	-	-	-	-	-	4	2	8	1	4	2	-	21	1.0
C25	Pancreas	-	-	-	-	-	-	-	2	3	2	7	2	6	3	2	2	-	29	1.3
C30-31	Nose, Sinuses etc.	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1	2	-	4	0.2
C32	Larynx	-	-	-	-	-	-	-	-	-	-	1	-	2	-	1	1	-	5	0.2
C33-34	Lung etc.	-	-	-	-	-	-	3	1	2	7	17	16	18	21	10	9	-	104	4.8
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	1	-	1	1	-	-	-	-	3	0.1
C40-41	Bone	1	1	3	1	-	-	-	-	-	-	1	1	-	1	1	-	-	10	0.5
C43	Melanoma of Skin	-	-	-	-	-	1	1	1	3	2	1	5	9	3	3	7	-	36	1.7
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	1	0.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	-	1	2	-	1	1	1	4	1	3	2	4	-	2	3	2	-	27	1.2
C50	Breast	-	-	-	1	1	7	22	50	84	109	93	80	79	69	33	27	-	655	30.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	3	-	1	2	-	6	0.3
C52	Vagina	-	-	-	-	-	-	-	-	2	-	1	1	-	1	1	3	-	9	0.4
C53	Cervix Uteri	-	-	-	-	1	-	1	3	14	13	23	25	27	24	15	11	-	157	7.2
C54	Corpus Uteri	-	-	-	-	-	-	-	3	3	12	12	16	18	13	8	4	-	89	4.1
C55	Uterus Unspecified	-	-	-	-	2	2	2	-	2	-	-	-	1	-	-	-	-	9	0.4
C56	Ovary etc.	-	-	-	1	1	1	2	9	12	15	23	15	19	16	12	8	-	134	6.1
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	2	-	-	-	-	-	-	-	2	0.1
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	-	-	-	-	-	-	1	-	-	-	2	-	-	1	-	2	-	6	0.3
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1	0.0
C67	Bladder	-	-	-	-	-	1	-	-	-	1	1	2	2	1	3	3	-	14	0.6
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	1	0.0
C70-72	Brain, Nervous System	-	1	3	-	-	2	1	3	3	8	5	2	2	4	1	-	-	35	1.6
C73	Thyroid	-	-	-	2	3	2	4	3	7	11	11	6	5	8	4	12	-	78	3.6
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	1	0.0
C81	Hodgkins Disease	-	-	-	-	2	2	1	1	3	-	1	2	3	-	1	-	-	16	0.7
C82-85,C96	NHL	-	-	-	-	1	1	2	5	2	6	10	8	12	10	8	6	-	71	3.3
C88	Malg Imn.Prol D	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	1	0.0
C90	Multiple Myeloma	-	-	-	-	-	-	-	2	2	5	6	8	10	14	11	11	-	69	3.2
C91	Lymphoid Leuk.	1	4	1	1	-	-	3	1	-	2	4	-	2	2	2	1	-	24	1.1
C92-94	Myeloid Leukaemia	2	2	-	1	1	1	2	6	5	4	2	8	4	3	2	5	-	48	2.2
C95	Leukaemia Uns	1	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	2	0.1
O&U	Other and Uns	-	-	-	-	-	-	-	-	-	3	3	5	3	2	2	5	-	23	1.1
	<b>All Sites</b>	<b>6</b>	<b>10</b>	<b>10</b>	<b>7</b>	<b>15</b>	<b>25</b>	<b>53</b>	<b>116</b>	<b>177</b>	<b>243</b>	<b>275</b>	<b>259</b>	<b>302</b>	<b>277</b>	<b>189</b>	<b>216</b>	<b>-</b>	<b>2180</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 2(a): Number (#) and Proportion (%) of Cancers by Site (ICD-10) and Method of Diagnosis - Males**

As on: 26/06/2020

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C01-02	Tongue	140	98.6	-	-	-	-	2	1.4	-	-	142	100.0
C03-06	Mouth	170	98.8	-	-	2	1.2	-	-	-	-	172	100.0
C07-08	Salivary Gland	7	100.0	-	-	-	-	-	-	-	-	7	100.0
C09	Tonsil	12	100.0	-	-	-	-	-	-	-	-	12	100.0
C10	Oth. Oropharynx	64	100.0	-	-	-	-	-	-	-	-	64	100.0
C11	Nasopharynx	12	92.3	1	7.7	-	-	-	-	-	-	13	100.0
C12-13	Hypopharynx	53	98.1	-	-	1	1.9	-	-	-	-	54	100.0
C14	Pharynx Unspecified	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C15	Oesophagus	79	92.9	2	2.4	-	-	4	4.7	-	-	85	100.0
C16	Stomach	174	96.7	3	1.7	-	-	3	1.7	-	-	180	100.0
C17	Small Intestine	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C18	Colon	61	93.8	-	-	3	4.6	1	1.5	-	-	65	100.0
C19-20	Rectum	119	96.0	2	1.6	-	-	3	2.4	-	-	124	100.0
C21	Anus & Anal Canal	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C22	Liver	25	32.5	52	67.5	-	-	-	-	-	-	77	100.0
C23-24	Gallbladder etc.	11	73.3	3	20.0	-	-	1	6.7	-	-	15	100.0
C25	Pancreas	30	69.8	12	27.9	-	-	1	2.3	-	-	43	100.0
C30-31	Nose, Sinuses etc.	8	88.9	-	-	-	-	1	11.1	-	-	9	100.0
C32	Larynx	118	97.5	1	0.8	2	1.7	-	-	-	-	121	100.0
C33-34	Lung etc.	427	82.0	93	17.9	1	0.2	-	-	-	-	521	100.0
C37-38	Other Thoracic Organs	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	14	100.0	-	-	-	-	-	-	-	-	14	100.0
C43	Melanoma of Skin	41	100.0	-	-	-	-	-	-	-	-	41	100.0
C44	Other Skin	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	25	100.0	-	-	-	-	-	-	-	-	25	100.0
C50	Breast	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C61	Prostate	102	95.3	1	0.9	2	1.9	2	1.9	-	-	107	100.0
C62	Testis	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C63	Other Male Genital	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C64	Kidney etc.	25	86.2	4	13.8	-	-	-	-	-	-	29	100.0
C65	Renal Pelvis	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	56	93.3	3	5.0	-	-	1	1.7	-	-	60	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	38	95.0	2	5.0	-	-	-	-	-	-	40	100.0
C73	Thyroid	21	100.0	-	-	-	-	-	-	-	-	21	100.0
C74	Adrenal Gland	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C81	Hodgkins Disease	20	100.0	-	-	-	-	-	-	-	-	20	100.0
C82-85,C96	NHL	128	99.2	1	0.8	-	-	-	-	-	-	129	100.0
C88	Malig Imm.Prol D	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C90	Multiple Myeloma	47	97.9	-	-	-	-	1	2.1	-	-	48	100.0
C91	Lymphoid Leuk.	20	100.0	-	-	-	-	-	-	-	-	20	100.0
C92-94	Myeloid Leukaemia	59	100.0	-	-	-	-	-	-	-	-	59	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	55	68.8	22	27.5	3	3.8	-	-	-	-	80	100.0
	<b>All Sites</b>	<b>2210</b>	<b>90.3</b>	<b>203</b>	<b>8.3</b>	<b>14</b>	<b>0.6</b>	<b>20</b>	<b>0.8</b>	<b>-</b>	<b>-</b>	<b>2447</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 2(b): Number (#) and Proportion (%) of Cancers by Site (ICD-10) and Method of Diagnosis - Females**

As on: 26/06/2020

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	10	90.9	-	-	-	-	1	9.1	-	-	11	100.0
C01-02	Tongue	55	96.5	-	-	1	1.8	1	1.8	-	-	57	100.0
C03-06	Mouth	109	99.1	-	-	1	0.9	-	-	-	-	110	100.0
C07-08	Salivary Gland	15	100.0	-	-	-	-	-	-	-	-	15	100.0
C09	Tonsil	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	3	75.0	-	-	1	25.0	-	-	-	-	4	100.0
C11	Nasopharynx	1	25.0	3	75.0	-	-	-	-	-	-	4	100.0
C12-13	Hypopharynx	11	100.0	-	-	-	-	-	-	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	38	95.0	1	2.5	-	-	1	2.5	-	-	40	100.0
C16	Stomach	60	93.8	3	4.7	1	1.6	-	-	-	-	64	100.0
C17	Small Intestine	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	50	94.3	2	3.8	-	-	1	1.9	-	-	53	100.0
C19-20	Rectum	85	93.4	4	4.4	-	-	2	2.2	-	-	91	100.0
C21	Anus & Anal Canal	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	17	77.3	5	22.7	-	-	-	-	-	-	22	100.0
C23-24	Gallbladder etc.	16	76.2	4	19.0	1	4.8	-	-	-	-	21	100.0
C25	Pancreas	24	82.8	5	17.2	-	-	-	-	-	-	29	100.0
C30-31	Nose, Sinuses etc.	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C32	Larynx	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C33-34	Lung etc.	95	91.3	9	8.7	-	-	-	-	-	-	104	100.0
C37-38	Other Thoracic Organs	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C40-41	Bone	10	100.0	-	-	-	-	-	-	-	-	10	100.0
C43	Melanoma of Skin	36	100.0	-	-	-	-	-	-	-	-	36	100.0
C44	Other Skin	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	26	96.3	1	3.7	-	-	-	-	-	-	27	100.0
C50	Breast	644	98.3	1	0.2	5	0.8	5	0.8	-	-	655	100.0
C51	Vulva	5	83.3	-	-	1	16.7	-	-	-	-	6	100.0
C52	Vagina	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C53	Cervix Uteri	153	97.5	1	0.6	2	1.3	1	0.6	-	-	157	100.0
C54	Corpus Uteri	88	98.9	1	1.1	-	-	-	-	-	-	89	100.0
C55	Uterus Unspecified	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C56	Ovary etc.	114	85.1	9	6.7	1	0.7	10	7.5	-	-	134	100.0
C57	Other Female Genital	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	14	100.0	-	-	-	-	-	-	-	-	14	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	34	97.1	1	2.9	-	-	-	-	-	-	35	100.0
C73	Thyroid	76	97.4	2	2.6	-	-	-	-	-	-	78	100.0
C74	Adrenal Gland	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	16	100.0	-	-	-	-	-	-	-	-	16	100.0
C82-85,C96	NHL	70	98.6	1	1.4	-	-	-	-	-	-	71	100.0
C88	Malig Imn.Prol D	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	68	98.6	-	-	1	1.4	-	-	-	-	69	100.0
C91	Lymphoid Leuk.	24	100.0	-	-	-	-	-	-	-	-	24	100.0
C92-94	Myeloid Leukaemia	48	100.0	-	-	-	-	-	-	-	-	48	100.0
C95	Leukaemia Uns	2	100.0	-	-	-	-	-	-	-	-	2	100.0
O&U	Other and Uns	12	52.2	8	34.8	3	13.0	-	-	-	-	23	100.0
	<b>All Sites</b>	<b>2077</b>	<b>95.3</b>	<b>63</b>	<b>2.9</b>	<b>18</b>	<b>0.8</b>	<b>22</b>	<b>1.0</b>	-	-	<b>2180</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 3(a): Number (#) and Proportion (%) of Cancers by Site (ICD-10) and Detailed Microscopic Diagnosis - Males**

As on: 26/06/2020

ICD 10	Site	Histology of Primary		Histology of Secondary		Cytology of Primary		Cytology of Metastasis		Blood Film		Bone Marrow		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C01-02	Tongue	135	6750.0	1	50.0	3	150.0	1	50.0	-	-	-	-	2	100.0
C03-06	Mouth	166	8300.0	-	-	3	150.0	1	50.0	-	-	-	-	2	100.0
C07-08	Salivary Gland	3	42.9	-	-	4	57.1	-	-	-	-	-	-	7	100.0
C09	Tonsil	11	91.7	-	-	1	8.3	-	-	-	-	-	-	12	100.0
C10	Oth. Oropharynx	52	81.2	2	3.1	4	6.2	6	9.4	-	-	-	-	64	100.0
C11	Nasopharynx	11	1100.0	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	46	4600.0	2	200.0	2	200.0	3	300.0	-	-	-	-	1	100.0
C14	Pharynx Unspecified	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C15	Oesophagus	76	1266.7	1	16.7	2	33.3	-	-	-	-	-	-	6	100.0
C16	Stomach	169	2816.7	1	16.7	-	-	4	66.7	-	-	-	-	6	100.0
C17	Small Intestine	5	500.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	59	1475.0	1	25.0	-	-	1	25.0	-	-	-	-	4	100.0
C19-20	Rectum	118	2360.0	-	-	1	20.0	-	-	-	-	-	-	5	100.0
C21	Anus & Anal Canal	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C22	Liver	21	40.4	-	-	4	7.7	-	-	-	-	-	-	52	100.0
C23-24	Gallbladder etc.	10	250.0	-	-	-	-	1	25.0	-	-	-	-	4	100.0
C25	Pancreas	14	107.7	-	-	8	61.5	8	61.5	-	-	-	-	13	100.0
C30-31	Nose, Sinuses etc.	7	700.0	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C32	Larynx	111	3700.0	1	33.3	3	100.0	3	100.0	-	-	-	-	3	100.0
C33-34	Lung etc.	346	368.1	16	17.0	39	41.5	26	27.7	-	-	-	-	94	100.0
C37-38	Other Thoracic Organs	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	13	92.9	-	-	1	7.1	-	-	-	-	-	-	14	100.0
C43	Melanoma of Skin	40	97.6	-	-	1	2.4	-	-	-	-	-	-	41	100.0
C44	Other Skin	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	23	92.0	-	-	2	8.0	-	-	-	-	-	-	25	100.0
C50	Breast	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	8	88.9	-	-	1	11.1	-	-	-	-	-	-	9	100.0
C61	Prostate	100	2000.0	1	20.0	1	20.0	-	-	-	-	-	-	5	100.0
C62	Testis	7	87.5	1	12.5	-	-	-	-	-	-	-	-	8	100.0
C63	Other Male Genital	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C64	Kidney etc.	24	600.0	-	-	1	25.0	-	-	-	-	-	-	4	100.0
C65	Renal Pelvis	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	53	1325.0	-	-	3	75.0	-	-	-	-	-	-	4	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	38	1900.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C73	Thyroid	19	90.5	-	-	2	9.5	-	-	-	-	-	-	21	100.0
C74	Adrenal Gland	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C81	Hodgkins Disease	18	90.0	-	-	2	10.0	-	-	-	-	-	-	20	100.0
C82-85,C96	NHL	100	714.3	-	-	6	42.9	2	14.3	7	50.0	13	92.9	14	100.0
C88	Malig Imm.Prol D	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C90	Multiple Myeloma	3	6.8	-	-	1	2.3	-	-	-	-	43	97.7	44	100.0
C91	Lymphoid Leuk.	3	15.0	-	-	-	-	-	-	12	60.0	5	25.0	20	100.0
C92-94	Myeloid Leukaemia	7	11.9	-	-	-	-	-	-	32	54.2	20	33.9	59	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	4.0	16	64.0	1	4.0	37	148.0	-	-	-	-	25	100.0
	<b>All Sites</b>	<b>1844</b>	<b>297.4</b>	<b>44</b>	<b>7.1</b>	<b>97</b>	<b>15.6</b>	<b>93</b>	<b>15.0</b>	<b>51</b>	<b>8.2</b>	<b>81</b>	<b>13.1</b>	<b>620</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 3(b): Number (#) and Proportion (%) of Cancers by Site (ICD-10) and Detailed Microscopic Diagnosis - Females**

As on: 26/06/2020

ICD 10	Site	Histology of Primary		Histology of Secondary		Cytology of Primary		Cytology of Metastasis		Blood Film		Bone Marrow		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	10	1000.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C01-02	Tongue	55	2750.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C03-06	Mouth	104	10400.0	-	-	2	200.0	3	300.0	-	-	-	-	1	100.0
C07-08	Salivary Gland	14	93.3	-	-	1	6.7	-	-	-	-	-	-	15	100.0
C09	Tonsil	2	200.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	3	300.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C11	Nasopharynx	-	-	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C12-13	Hypopharynx	11	100.0	-	-	-	-	-	-	-	-	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	36	1800.0	-	-	1	50.0	1	50.0	-	-	-	-	2	100.0
C16	Stomach	60	1500.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C17	Small Intestine	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	46	1533.3	2	66.7	1	33.3	1	33.3	-	-	-	-	3	100.0
C19-20	Rectum	85	1416.7	-	-	-	-	-	-	-	-	-	-	6	100.0
C21	Anus & Anal Canal	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	17	340.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C23-24	Gallbladder etc.	12	240.0	-	-	-	-	4	80.0	-	-	-	-	5	100.0
C25	Pancreas	19	380.0	2	40.0	1	20.0	2	40.0	-	-	-	-	5	100.0
C30-31	Nose, Sinuses etc.	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C32	Larynx	4	80.0	-	-	-	-	1	20.0	-	-	-	-	5	100.0
C33-34	Lung etc.	77	855.6	1	11.1	10	111.1	7	77.8	-	-	-	-	9	100.0
C37-38	Other Thoracic Organs	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C40-41	Bone	10	100.0	-	-	-	-	-	-	-	-	-	-	10	100.0
C43	Melanoma of Skin	36	100.0	-	-	-	-	-	-	-	-	-	-	36	100.0
C44	Other Skin	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	25	2500.0	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C50	Breast	573	5209.1	-	-	68	618.2	3	27.3	-	-	-	-	11	100.0
C51	Vulva	5	500.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C52	Vagina	8	88.9	-	-	1	11.1	-	-	-	-	-	-	9	100.0
C53	Cervix Uteri	153	3825.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C54	Corpus Uteri	87	8700.0	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C55	Uterus Unspecified	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C56	Ovary etc.	86	430.0	5	25.0	11	55.0	12	60.0	-	-	-	-	20	100.0
C57	Other Female Genital	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	4	400.0	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C67	Bladder	14	100.0	-	-	-	-	-	-	-	-	-	-	14	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	34	3400.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	57	2850.0	1	50.0	18	900.0	-	-	-	-	-	-	2	100.0
C74	Adrenal Gland	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	16	100.0	-	-	-	-	-	-	-	-	-	-	16	100.0
C82-85,C96	NHL	58	966.7	1	16.7	5	83.3	-	-	1	16.7	5	83.3	6	100.0
C88	Malg Imn.Prol D	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	8	13.1	-	-	-	-	-	-	-	-	60	98.4	61	100.0
C91	Lymphoid Leuk.	3	12.5	-	-	-	-	-	-	14	58.3	7	29.2	24	100.0
C92-94	Myeloid Leukaemia	5	10.4	-	-	-	-	-	-	26	54.2	17	35.4	48	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	2	100.0	-	-	2	100.0
O&U	Other and Uns	-	-	6	54.5	2	18.2	4	36.4	-	-	-	-	11	100.0
	<b>All Sites</b>	<b>1763</b>	<b>457.9</b>	<b>19</b>	<b>4.9</b>	<b>123</b>	<b>31.9</b>	<b>40</b>	<b>10.4</b>	<b>43</b>	<b>11.2</b>	<b>89</b>	<b>23.1</b>	<b>385</b>	<b>100.0</b>



**Table 4(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Groups - Males**

As on: 29/06/2020

ICD 10	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	2	66.7	-	-	-	-	1	33.3	3	100.0
C01-02	Tongue	20	14.1	8	5.6	89	62.7	25	17.6	142	100.0
C03-06	Mouth	31	18.0	10	5.8	97	56.4	34	19.8	172	100.0
C07-08	Salivary Gland	1	14.3	1	14.3	1	14.3	4	57.1	7	100.0
C09	Tonsil	-	-	-	-	10	83.3	2	16.7	12	100.0
C10	Oth. Oropharynx	3	4.7	3	4.7	38	59.4	20	31.2	64	100.0
C11	Nasopharynx	3	23.1	-	-	8	61.5	2	15.4	13	100.0
C12-13	Hypopharynx	8	14.8	4	7.4	30	55.6	12	22.2	54	100.0
C14	Pharynx Unspecified	-	-	-	-	2	100.0	-	-	2	100.0
C15	Oesophagus	5	5.9	1	1.2	39	45.9	40	47.1	85	100.0
C16	Stomach	34	18.9	19	10.6	53	29.4	74	41.1	180	100.0
C17	Small Intestine	3	50.0	1	16.7	1	16.7	1	16.7	6	100.0
C18	Colon	24	36.9	7	10.8	17	26.2	17	26.2	65	100.0
C19-20	Rectum	24	19.4	12	9.7	63	50.8	25	20.2	124	100.0
C21	Anus & Anal Canal	-	-	-	-	6	66.7	3	33.3	9	100.0
C22	Liver	13	16.9	5	6.5	9	11.7	50	64.9	77	100.0
C23-24	Gallbladder etc.	3	20.0	2	13.3	2	13.3	8	53.3	15	100.0
C25	Pancreas	7	16.3	1	2.3	11	25.6	24	55.8	43	100.0
C30-31	Nose, Sinuses etc.	3	33.3	-	-	3	33.3	3	33.3	9	100.0
C32	Larynx	10	8.3	15	12.4	71	58.7	25	20.7	121	100.0
C33-34	Lung etc.	31	6.0	22	4.2	213	40.9	255	48.9	521	100.0
C37-38	Other Thoracic Organs	1	50.0	-	-	-	-	1	50.0	2	100.0
C40-41	Bone	1	7.1	3	21.4	7	50.0	3	21.4	14	100.0
C43	Melanoma of Skin	11	26.8	6	14.6	17	41.5	7	17.1	41	100.0
C44	Other Skin	1	100.0	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	4	16.0	8	32.0	11	44.0	2	8.0	25	100.0
C50	Breast	-	-	1	50.0	1	50.0	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	11.1	2	22.2	4	44.4	2	22.2	9	100.0
C61	Prostate	24	22.4	34	31.8	29	27.1	20	18.7	107	100.0
C62	Testis	3	37.5	2	25.0	2	25.0	1	12.5	8	100.0
C63	Other Male Genital	1	50.0	-	-	1	50.0	-	-	2	100.0
C64	Kidney etc.	7	24.1	5	17.2	6	20.7	11	37.9	29	100.0
C65	Renal Pelvis	1	100.0	-	-	-	-	-	-	1	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-
C67	Bladder	25	41.7	9	15.0	12	20.0	14	23.3	60	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	1	100.0	-	-	1	100.0
C70-72	Brain, Nervous System	15	37.5	19	47.5	1	2.5	5	12.5	40	100.0
C73	Thyroid	10	47.6	5	23.8	4	19.0	2	9.5	21	100.0
C74	Adrenal Gland	1	50.0	1	50.0	-	-	-	-	2	100.0
C81	Hodgkins Disease	2	10.0	5	25.0	9	45.0	4	20.0	20	100.0
C82-85,C96	NHL	18	14.0	9	7.0	47	36.4	55	42.6	129	100.0
C88	Malig Imn.Prol D	1	50.0	-	-	-	-	1	50.0	2	100.0
C90	Multiple Myeloma	3	6.2	6	12.5	24	50.0	15	31.2	48	100.0
C91	Lymphoid Leuk.	2	10.0	1	5.0	6	30.0	11	55.0	20	100.0
C92-94	Myeloid Leukaemia	8	13.6	2	3.4	26	44.1	23	39.0	59	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	5	6.2	3	3.8	19	23.8	53	66.2	80	100.0
	<b>All Sites</b>	<b>370</b>	<b>15.1</b>	<b>232</b>	<b>9.5</b>	<b>990</b>	<b>40.5</b>	<b>855</b>	<b>34.9</b>	<b>2447</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 4(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Groups - Females**

ICD 10	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	3	27.3	1	9.1	5	45.5	2	18.2	11	100.0
C01-02	Tongue	10	17.5	6	10.5	33	57.9	8	14.0	57	100.0
C03-06	Mouth	12	10.9	6	5.5	69	62.7	23	20.9	110	100.0
C07-08	Salivary Gland	4	26.7	5	33.3	5	33.3	1	6.7	15	100.0
C09	Tonsil	-	-	-	-	2	66.7	1	33.3	3	100.0
C10	Oth. Oropharynx	1	25.0	-	-	1	25.0	2	50.0	4	100.0
C11	Nasopharynx	1	25.0	-	-	1	25.0	2	50.0	4	100.0
C12-13	Hypopharynx	1	9.1	-	-	10	90.9	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	6	15.0	1	2.5	18	45.0	15	37.5	40	100.0
C16	Stomach	7	10.9	7	10.9	17	26.6	33	51.6	64	100.0
C17	Small Intestine	-	-	1	100.0	-	-	-	-	1	100.0
C18	Colon	12	22.6	13	24.5	17	32.1	11	20.8	53	100.0
C19-20	Rectum	20	22.0	7	7.7	43	47.3	21	23.1	91	100.0
C21	Anus & Anal Canal	-	-	-	-	2	66.7	1	33.3	3	100.0
C22	Liver	4	18.2	4	18.2	3	13.6	11	50.0	22	100.0
C23-24	Gallbladder etc.	7	33.3	-	-	3	14.3	11	52.4	21	100.0
C25	Pancreas	4	13.8	8	27.6	5	17.2	12	41.4	29	100.0
C30-31	Nose, Sinuses etc.	-	-	-	-	2	50.0	2	50.0	4	100.0
C32	Larynx	1	20.0	-	-	3	60.0	1	20.0	5	100.0
C33-34	Lung etc.	9	8.7	8	7.7	35	33.7	52	50.0	104	100.0
C37-38	Other Thoracic Organs	-	-	1	33.3	1	33.3	1	33.3	3	100.0
C40-41	Bone	-	-	2	20.0	5	50.0	3	30.0	10	100.0
C43	Melanoma of Skin	9	25.0	6	16.7	14	38.9	7	19.4	36	100.0
C44	Other Skin	1	100.0	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	8	29.6	8	29.6	8	29.6	3	11.1	27	100.0
C50	Breast	82	12.5	146	22.3	332	50.7	95	14.5	655	100.0
C51	Vulva	1	16.7	1	16.7	3	50.0	1	16.7	6	100.0
C52	Vagina	-	-	2	22.2	5	55.6	2	22.2	9	100.0
C53	Cervix Uteri	17	10.8	13	8.3	99	63.1	28	17.8	157	100.0
C54	Corpus Uteri	28	31.5	24	27.0	25	28.1	12	13.5	89	100.0
C55	Uterus Unspecified	3	33.3	2	22.2	3	33.3	1	11.1	9	100.0
C56	Ovary etc.	24	17.9	28	20.9	46	34.3	36	26.9	134	100.0
C57	Other Female Genital	-	-	2	100.0	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	2	33.3	-	-	2	33.3	2	33.3	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	1	100.0	-	-	1	100.0
C67	Bladder	5	35.7	1	7.1	5	35.7	3	21.4	14	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	1	100.0	-	-	1	100.0
C70-72	Brain, Nervous System	12	34.3	21	60.0	1	2.9	1	2.9	35	100.0
C73	Thyroid	28	35.9	9	11.5	20	25.6	21	26.9	78	100.0
C74	Adrenal Gland	-	-	-	-	1	100.0	-	-	1	100.0
C81	Hodgkins Disease	3	18.8	1	6.2	10	62.5	2	12.5	16	100.0
C82-85,C96	NHL	9	12.7	2	2.8	29	40.8	31	43.7	71	100.0
C88	Malig Imn.Prol D	-	-	-	-	1	100.0	-	-	1	100.0
C90	Multiple Myeloma	7	10.1	7	10.1	29	42.0	26	37.7	69	100.0
C91	Lymphoid Leuk.	4	16.7	-	-	6	25.0	14	58.3	24	100.0
C92-94	Myeloid Leukaemia	6	12.5	4	8.3	18	37.5	20	41.7	48	100.0
C95	Leukaemia Uns	-	-	-	-	1	50.0	1	50.0	2	100.0
O&U	Other and Uns	2	8.7	-	-	2	8.7	19	82.6	23	100.0
	<b>All Sites</b>	<b>353</b>	<b>16.2</b>	<b>347</b>	<b>15.9</b>	<b>942</b>	<b>43.2</b>	<b>538</b>	<b>24.7</b>	<b>2180</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 5(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Males (Treatment Only at RI)**

As on: 29/06/2020

ICD 10	Site	Clinical Extent of Disease											
		Localised		Regional		Distant		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-
C01-02	Tongue	31	34.8	55	61.8	3	3.4	-	-	-	-	89	100.0
C03-06	Mouth	23	23.7	67	69.1	6	6.2	1	1.0	-	-	97	100.0
C07-08	Salivary Gland	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C09	Tonsil	3	30.0	5	50.0	2	20.0	-	-	-	-	10	100.0
C10	Oth. Oropharynx	7	18.4	28	73.7	2	5.3	1	2.6	-	-	38	100.0
C11	Nasopharynx	1	12.5	7	87.5	-	-	-	-	-	-	8	100.0
C12-13	Hypopharynx	3	10.0	24	80.0	3	10.0	-	-	-	-	30	100.0
C14	Pharynx Unspecified	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C15	Oesophagus	5	12.8	14	35.9	20	51.3	-	-	-	-	39	100.0
C16	Stomach	9	17.0	20	37.7	24	45.3	-	-	-	-	53	100.0
C17	Small Intestine	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C18	Colon	2	11.8	7	41.2	8	47.1	-	-	-	-	17	100.0
C19-20	Rectum	15	23.8	35	55.6	13	20.6	-	-	-	-	63	100.0
C21	Anus & Anal Canal	1	16.7	4	66.7	1	16.7	-	-	-	-	6	100.0
C22	Liver	1	11.1	3	33.3	5	55.6	-	-	-	-	9	100.0
C23-24	Gallbladder etc.	-	-	-	-	2	100.0	-	-	-	-	2	100.0
C25	Pancreas	-	-	3	27.3	8	72.7	-	-	-	-	11	100.0
C30-31	Nose, Sinuses etc.	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C32	Larynx	36	50.7	32	45.1	3	4.2	-	-	-	-	71	100.0
C33-34	Lung etc.	13	6.1	82	38.5	118	55.4	-	-	-	-	213	100.0
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	-	-	-
C40-41	Bone	5	71.4	1	14.3	1	14.3	-	-	-	-	7	100.0
C43	Melanoma of Skin	8	47.1	6	35.3	3	17.6	-	-	-	-	17	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	27.3	4	36.4	4	36.4	-	-	-	-	11	100.0
C50	Breast	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	25.0	3	75.0	-	-	-	-	-	-	4	100.0
C61	Prostate	13	44.8	5	17.2	11	37.9	-	-	-	-	29	100.0
C62	Testis	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	3	50.0	-	-	3	50.0	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	7	58.3	-	-	5	41.7	-	-	-	-	12	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	1	25.0	2	50.0	1	25.0	-	-	-	-	4	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	1	11.1	7	77.8	-	-	1	11.1	-	-	9	100.0
C82-85,C96	NHL	4	8.5	22	46.8	3	6.4	18	38.3	-	-	47	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	24	100.0	-	-	24	100.0
C91	Lymphoid Leuk.	-	-	-	-	-	-	6	100.0	-	-	6	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	26	100.0	-	-	26	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	-	-	-	-	17	89.5	2	10.5	-	-	19	100.0
	<b>All Sites</b>	<b>202</b>	<b>20.4</b>	<b>442</b>	<b>44.6</b>	<b>267</b>	<b>27.0</b>	<b>79</b>	<b>8.0</b>	<b>-</b>	<b>-</b>	<b>990</b>	<b>100.0</b>

**Table 5(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Females (Treatment Only at RI)**

As on: 29/06/2020

ICD 10	Site	Clinical Extent of Disease											
		Localised		Regional		Distant		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	2	40.0	3	60.0	-	-	-	-	-	-	5	100.0
C01-02	Tongue	14	42.4	17	51.5	1	3.0	1	3.0	-	-	33	100.0
C03-06	Mouth	21	30.4	45	65.2	3	4.3	-	-	-	-	69	100.0
C07-08	Salivary Gland	1	20.0	3	60.0	1	20.0	-	-	-	-	5	100.0
C09	Tonsil	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C11	Nasopharynx	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C12-13	Hypopharynx	2	20.0	6	60.0	2	20.0	-	-	-	-	10	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	3	16.7	9	50.0	6	33.3	-	-	-	-	18	100.0
C16	Stomach	4	23.5	4	23.5	9	52.9	-	-	-	-	17	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	-	-
C18	Colon	4	23.5	4	23.5	8	47.1	1	5.9	-	-	17	100.0
C19-20	Rectum	8	18.6	31	72.1	4	9.3	-	-	-	-	43	100.0
C21	Anus & Anal Canal	-	-	1	50.0	-	-	1	50.0	-	-	2	100.0
C22	Liver	1	33.3	1	33.3	1	33.3	-	-	-	-	3	100.0
C23-24	Gallbladder etc.	-	-	1	33.3	2	66.7	-	-	-	-	3	100.0
C25	Pancreas	-	-	2	40.0	3	60.0	-	-	-	-	5	100.0
C30-31	Nose, Sinuses etc.	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C32	Larynx	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C33-34	Lung etc.	-	-	9	25.7	26	74.3	-	-	-	-	35	100.0
C37-38	Other Thoracic Organs	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C40-41	Bone	2	40.0	2	40.0	1	20.0	-	-	-	-	5	100.0
C43	Melanoma of Skin	8	57.1	4	28.6	2	14.3	-	-	-	-	14	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	2	25.0	2	25.0	4	50.0	-	-	-	-	8	100.0
C50	Breast	85	25.6	196	59.0	51	15.4	-	-	-	-	332	100.0
C51	Vulva	2	66.7	-	-	1	33.3	-	-	-	-	3	100.0
C52	Vagina	1	20.0	3	60.0	1	20.0	-	-	-	-	5	100.0
C53	Cervix Uteri	34	34.3	49	49.5	15	15.2	1	1.0	-	-	99	100.0
C54	Corpus Uteri	16	64.0	6	24.0	3	12.0	-	-	-	-	25	100.0
C55	Uterus Unspecified	1	33.3	-	-	2	66.7	-	-	-	-	3	100.0
C56	Ovary etc.	11	23.9	6	13.0	28	60.9	1	2.2	-	-	46	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	6	30.0	6	30.0	8	40.0	-	-	-	-	20	100.0
C74	Adrenal Gland	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	-	-	8	80.0	-	-	2	20.0	-	-	10	100.0
C82-85,C96	NHL	2	6.9	20	69.0	2	6.9	5	17.2	-	-	29	100.0
C88	Malig Imm.Prol D	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C90	Multiple Myeloma	-	-	-	-	-	-	29	100.0	-	-	29	100.0
C91	Lymphoid Leuk.	-	-	-	-	-	-	6	100.0	-	-	6	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	18	100.0	-	-	18	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	1	100.0	-	-	1	100.0
O&U	Other and Uns	-	-	-	-	2	100.0	-	-	-	-	2	100.0
	<b>All Sites</b>	<b>241</b>	<b>25.6</b>	<b>446</b>	<b>47.3</b>	<b>188</b>	<b>20.0</b>	<b>67</b>	<b>7.1</b>	-	-	<b>942</b>	<b>100.0</b>

**Table 6(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease – Males (Prior & Treatment at RI)**

As on: 29/06/2020

ICD 10	Site	Clinical Extent of Disease											
		Localised		Regional		Distant		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-
C01-02	Tongue	1	12.5	6	75.0	-	-	1	12.5	-	-	8	100.0
C03-06	Mouth	-	-	5	50.0	-	-	5	50.0	-	-	10	100.0
C07-08	Salivary Gland	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	2	66.7	-	-	1	33.3	-	-	3	100.0
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	-
C12-13	Hypopharynx	-	-	2	50.0	-	-	2	50.0	-	-	4	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C16	Stomach	1	5.3	6	31.6	7	36.8	5	26.3	-	-	19	100.0
C17	Small Intestine	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C18	Colon	-	-	3	42.9	1	14.3	3	42.9	-	-	7	100.0
C19-20	Rectum	-	-	4	33.3	3	25.0	5	41.7	-	-	12	100.0
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	-
C22	Liver	-	-	1	20.0	3	60.0	1	20.0	-	-	5	100.0
C23-24	Gallbladder etc.	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C25	Pancreas	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C30-31	Nose, Sinuses etc.	-	-	-	-	-	-	-	-	-	-	-	-
C32	Larynx	4	26.7	3	20.0	1	6.7	7	46.7	-	-	15	100.0
C33-34	Lung etc.	-	-	5	22.7	9	40.9	8	36.4	-	-	22	100.0
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	-	-	-
C40-41	Bone	-	-	-	-	-	-	3	100.0	-	-	3	100.0
C43	Melanoma of Skin	2	33.3	-	-	1	16.7	3	50.0	-	-	6	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	37.5	1	12.5	1	12.5	3	37.5	-	-	8	100.0
C50	Breast	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	1	50.0	1	50.0	-	-	-	-	2	100.0
C61	Prostate	1	2.9	3	8.8	17	50.0	13	38.2	-	-	34	100.0
C62	Testis	-	-	1	50.0	1	50.0	-	-	-	-	2	100.0
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	-	-	-	-	2	40.0	3	60.0	-	-	5	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	-	-	2	22.2	-	-	7	77.8	-	-	9	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-
C70-72	Brain, Nervous System	4	21.1	4	21.1	-	-	11	57.9	-	-	19	100.0
C73	Thyroid	1	20.0	1	20.0	1	20.0	2	40.0	-	-	5	100.0
C74	Adrenal Gland	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C81	Hodgkins Disease	-	-	1	20.0	-	-	4	80.0	-	-	5	100.0
C82-85,C96	NHL	-	-	3	33.3	1	11.1	5	55.6	-	-	9	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	6	100.0	-	-	6	100.0
C91	Lymphoid Leuk.	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	2	100.0	-	-	2	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	-	-	-	-	1	33.3	2	66.7	-	-	3	100.0
	<b>All Sites</b>	<b>18</b>	<b>7.8</b>	<b>57</b>	<b>24.6</b>	<b>51</b>	<b>22.0</b>	<b>106</b>	<b>45.7</b>	<b>-</b>	<b>-</b>	<b>232</b>	<b>100.0</b>

**Table 6(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease – Females (Prior & Treatment at RI)**

As on: 29/06/2020

ICD 10	Site	Clinical Extent of Disease												
		Localised		Regional		Distant		Others		Unknown		Total		
		#	%	#	%	#	%	#	%	#	%	#	%	
C00	Lip	-	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C01-02	Tongue	1	16.7	2	33.3	-	-	3	50.0	-	-	6	100.0	
C03-06	Mouth	1	16.7	1	16.7	-	-	4	66.7	-	-	6	100.0	
C07-08	Salivary Gland	2	40.0	1	20.0	1	20.0	1	20.0	-	-	5	100.0	
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	-	-	-	-	
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	-	
C12-13	Hypopharynx	-	-	-	-	-	-	-	-	-	-	-	-	
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	
C15	Oesophagus	-	-	1	100.0	-	-	-	-	-	-	1	100.0	
C16	Stomach	1	14.3	2	28.6	2	28.6	2	28.6	-	-	7	100.0	
C17	Small Intestine	-	-	-	-	-	-	1	100.0	-	-	1	100.0	
C18	Colon	2	15.4	4	30.8	4	30.8	3	23.1	-	-	13	100.0	
C19-20	Rectum	-	-	2	28.6	2	28.6	3	42.9	-	-	7	100.0	
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	-	
C22	Liver	-	-	2	50.0	-	-	2	50.0	-	-	4	100.0	
C23-24	Gallbladder etc.	-	-	-	-	-	-	-	-	-	-	-	-	
C25	Pancreas	1	12.5	3	37.5	3	37.5	1	12.5	-	-	8	100.0	
C30-31	Nose, Sinuses etc.	-	-	-	-	-	-	-	-	-	-	-	-	
C32	Larynx	-	-	-	-	-	-	-	-	-	-	-	-	
C33-34	Lung etc.	-	-	3	37.5	4	50.0	1	12.5	-	-	8	100.0	
C37-38	Other Thoracic Organs	-	-	-	-	-	-	1	100.0	-	-	1	100.0	
C40-41	Bone	-	-	-	-	-	-	2	100.0	-	-	2	100.0	
C43	Melanoma of Skin	1	16.7	2	33.3	-	-	3	50.0	-	-	6	100.0	
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-	
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	
C47+C49	Conn. & Soft Tissue	3	37.5	2	25.0	-	-	3	37.5	-	-	8	100.0	
C50	Breast	36	24.7	51	34.9	5	3.4	54	37.0	-	-	146	100.0	
C51	Vulva	-	-	-	-	-	-	1	100.0	-	-	1	100.0	
C52	Vagina	-	-	1	50.0	-	-	1	50.0	-	-	2	100.0	
C53	Cervix Uteri	3	23.1	5	38.5	-	-	5	38.5	-	-	13	100.0	
C54	Corpus Uteri	8	33.3	5	20.8	2	8.3	9	37.5	-	-	24	100.0	
C55	Uterus Unspecified	-	-	-	-	1	50.0	1	50.0	-	-	2	100.0	
C56	Ovary etc.	6	21.4	3	10.7	5	17.9	14	50.0	-	-	28	100.0	
C57	Other Female Genital	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0	
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	
C64	Kidney etc.	-	-	-	-	-	-	-	-	-	-	-	-	
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	
C67	Bladder	-	-	-	-	-	-	1	100.0	-	-	1	100.0	
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-	
C70-72	Brain, Nervous System	5	23.8	6	28.6	1	4.8	9	42.9	-	-	21	100.0	
C73	Thyroid	3	33.3	1	11.1	-	-	5	55.6	-	-	9	100.0	
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	
C81	Hodgkins Disease	-	-	-	-	-	-	1	100.0	-	-	1	100.0	
C82-85,C96	NHL	-	-	-	-	-	-	2	100.0	-	-	2	100.0	
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	
C90	Multiple Myeloma	-	-	-	-	-	-	7	100.0	-	-	7	100.0	
C91	Lymphoid Leuk.	-	-	-	-	-	-	-	-	-	-	-	-	
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	4	100.0	-	-	4	100.0	
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	
O&U	Other and Uns	-	-	-	-	-	-	-	-	-	-	-	-	
	<b>All Sites</b>	<b>74</b>	<b>21.3</b>	<b>98</b>	<b>28.2</b>	<b>30</b>	<b>8.6</b>	<b>145</b>	<b>41.8</b>	<b>-</b>	<b>-</b>	<b>347</b>	<b>100.0</b>	

**Table 7(a): Number (#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment – Males (Treatment Only at RI)**

ICD 10	Site	Type of Treatment																				
		Surgery		R-Therapy		C-Therapy		S+R		S+C		R+C		S+R+C		Others		Unknown		Total		
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C01-02	Tongue	28	31.5	10	11.2	-	-	29	32.6	-	-	15	16.9	7	7.9	-	-	-	-	-	89	100.0
C03-06	Mouth	19	19.6	23	23.7	-	-	26	26.8	-	-	19	19.6	10	10.3	-	-	-	-	-	97	100.0
C07-08	Salivary Gland	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C09	Tonsil	1	10.0	2	20.0	-	-	-	-	-	-	7	70.0	-	-	-	-	-	-	-	10	100.0
C10	Oth. Oropharynx	1	2.6	14	36.8	1	2.6	1	2.6	-	-	21	55.3	-	-	-	-	-	-	-	38	100.0
C11	Nasopharynx	-	-	3	37.5	-	-	-	-	-	-	5	62.5	-	-	-	-	-	-	-	8	100.0
C12-13	Hypopharynx	1	3.3	11	36.7	-	-	1	3.3	-	-	14	46.7	3	10.0	-	-	-	-	-	30	100.0
C14	Pharynx Unspecified	-	-	1	50.0	-	-	1	50.0	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C15	Oesophagus	1	2.6	29	74.4	-	-	-	-	2	5.1	7	17.9	-	-	-	-	-	-	-	39	100.0
C16	Stomach	8	15.1	16	30.2	10	18.9	-	-	8	15.1	10	18.9	1	1.9	-	-	-	-	-	53	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	1	100.0
C18	Colon	3	17.6	1	5.9	9	52.9	-	-	4	23.5	-	-	-	-	-	-	-	-	-	17	100.0
C19-20	Rectum	12	19.0	13	20.6	4	6.3	5	7.9	2	3.2	9	14.3	18	28.6	-	-	-	-	-	63	100.0
C21	Anus & Anal Canal	-	-	3	50.0	-	-	-	-	-	-	2	33.3	1	16.7	-	-	-	-	-	6	100.0
C22	Liver	1	11.1	1	11.1	6	66.7	-	-	-	-	-	-	-	-	1	11.1	-	-	-	9	100.0
C23-24	Gallbladder etc.	-	-	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C25	Pancreas	-	-	1	9.1	10	90.9	-	-	-	-	-	-	-	-	-	-	-	-	-	11	100.0
C30-31	Nose, Sinuses etc.	1	33.3	-	-	-	-	-	-	-	-	2	66.7	-	-	-	-	-	-	-	3	100.0
C32	Larynx	8	11.3	39	54.9	-	-	8	11.3	-	-	12	16.9	4	5.6	-	-	-	-	-	71	100.0
C33-34	Lung etc.	2	0.9	124	58.2	23	10.8	-	-	1	0.5	63	29.6	-	-	-	-	-	-	-	213	100.0
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40-41	Bone	1	14.3	1	14.3	-	-	1	14.3	3	42.9	-	-	1	14.3	-	-	-	-	-	7	100.0
C43	Melanoma of Skin	13	76.5	2	11.8	-	-	1	5.9	-	-	1	5.9	-	-	-	-	-	-	-	17	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	27.3	3	27.3	1	9.1	2	18.2	-	-	1	9.1	1	9.1	-	-	-	-	-	11	100.0
C50	Breast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	4	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	100.0
C61	Prostate	-	-	2	6.9	-	-	-	-	-	-	-	-	-	-	27	93.1	-	-	-	29	100.0
C62	Testis	-	-	-	-	1	50.0	-	-	1	50.0	-	-	-	-	-	-	-	-	-	2	100.0
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	3	50.0	1	16.7	-	-	-	-	-	-	2	33.3	-	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	6	50.0	2	16.7	-	-	1	8.3	1	8.3	1	8.3	-	-	1	8.3	-	-	-	12	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	-	-	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	3	75.0	1	25.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	1	11.1	5	55.6	-	-	-	-	3	33.3	-	-	-	-	-	-	-	9	100.0
C82-85,C96	NHL	-	-	3	6.4	36	76.6	-	-	-	-	7	14.9	-	-	1	2.1	-	-	-	47	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	19	79.2	-	-	-	-	3	12.5	-	-	2	8.3	-	-	-	24	100.0
C91	Lymphoid Leuk.	-	-	-	-	4	66.7	-	-	-	-	2	33.3	-	-	-	-	-	-	-	6	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	26	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	26	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	5.3	11	57.9	1	5.3	-	-	-	-	6	31.6	-	-	-	-	-	-	-	19	100.0
	All Sites	120	12.1	320	32.3	157	15.9	77	7.8	22	2.2	215	21.7	46	4.6	33	3.3	-	-	-	990	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97









**Table 9(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment – Males (Treatment Only at RI)**

As on: 29/06/2020

ICD 10	Site	Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C01-02	Tongue	64	43.5	61	41.5	22	15.0	-	-	-	-	-	-	147	100.0
C03-06	Mouth	55	34.0	78	48.1	29	17.9	-	-	-	-	-	-	162	100.0
C07-08	Salivary Gland	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C09	Tonsil	1	5.9	9	52.9	7	41.2	-	-	-	-	-	-	17	100.0
C10	Oth. Oropharynx	2	3.3	36	60.0	22	36.7	-	-	-	-	-	-	60	100.0
C11	Nasopharynx	-	-	8	61.5	5	38.5	-	-	-	-	-	-	13	100.0
C12-13	Hypopharynx	5	9.8	29	56.9	17	33.3	-	-	-	-	-	-	51	100.0
C14	Pharynx Unspecified	1	33.3	2	66.7	-	-	-	-	-	-	-	-	3	100.0
C15	Oesophagus	3	6.2	36	75.0	9	18.8	-	-	-	-	-	-	48	100.0
C16	Stomach	17	23.3	27	37.0	29	39.7	-	-	-	-	-	-	73	100.0
C17	Small Intestine	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C18	Colon	7	33.3	1	4.8	13	61.9	-	-	-	-	-	-	21	100.0
C19-20	Rectum	37	32.2	45	39.1	33	28.7	-	-	-	-	-	-	115	100.0
C21	Anus & Anal Canal	1	10.0	6	60.0	3	30.0	-	-	-	-	-	-	10	100.0
C22	Liver	1	11.1	1	11.1	6	66.7	-	-	1	11.1	-	-	9	100.0
C23-24	Gallbladder etc.	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C25	Pancreas	-	-	1	9.1	10	90.9	-	-	-	-	-	-	11	100.0
C30-31	Nose, Sinuses etc.	1	20.0	2	40.0	2	40.0	-	-	-	-	-	-	5	100.0
C32	Larynx	20	20.2	63	63.6	16	16.2	-	-	-	-	-	-	99	100.0
C33-34	Lung etc.	3	1.1	187	67.5	87	31.4	-	-	-	-	-	-	277	100.0
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40-41	Bone	6	46.2	3	23.1	4	30.8	-	-	-	-	-	-	13	100.0
C43	Melanoma of Skin	14	73.7	4	21.1	1	5.3	-	-	-	-	-	-	19	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	6	37.5	7	43.8	3	18.8	-	-	-	-	-	-	16	100.0
C50	Breast	-	-	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C61	Prostate	-	-	12	28.6	3	7.1	27	64.3	-	-	-	-	42	100.0
C62	Testis	1	33.3	-	-	2	66.7	-	-	-	-	-	-	3	100.0
C63	Other Male Genital	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C64	Kidney etc.	3	37.5	3	37.5	2	25.0	-	-	-	-	-	-	8	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	8	53.3	4	26.7	2	13.3	-	-	1	6.7	-	-	15	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	1	50.0	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C73	Thyroid	3	75.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	4	33.3	8	66.7	-	-	-	-	-	-	12	100.0
C82-85,C96	NHL	-	-	10	18.5	43	79.6	-	-	1	1.9	-	-	54	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	3	11.1	22	81.5	-	-	2	7.4	-	-	27	100.0
C91	Lymphoid Leuk.	-	-	2	25.0	6	75.0	-	-	-	-	-	-	8	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	26	100.0	-	-	-	-	-	-	26	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	4.0	17	68.0	7	28.0	-	-	-	-	-	-	25	100.0
	<b>All Sites</b>	<b>265</b>	<b>18.8</b>	<b>668</b>	<b>47.4</b>	<b>443</b>	<b>31.4</b>	<b>28</b>	<b>2.0</b>	<b>5</b>	<b>0.4</b>	<b>-</b>	<b>-</b>	<b>1409</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 9(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment – Females (Treatment Only at RI)**

As on: 29/06/2020

ICD 10	Site	Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	16.7	4	66.7	1	16.7	-	-	-	-	-	-	6	100.0
C01-02	Tongue	24	52.2	17	37.0	5	10.9	-	-	-	-	-	-	46	100.0
C03-06	Mouth	29	29.0	53	53.0	18	18.0	-	-	-	-	-	-	100	100.0
C07-08	Salivary Gland	3	60.0	2	40.0	-	-	-	-	-	-	-	-	5	100.0
C09	Tonsil	-	-	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C11	Nasopharynx	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	1	7.1	9	64.3	4	28.6	-	-	-	-	-	-	14	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	2	8.7	17	73.9	4	17.4	-	-	-	-	-	-	23	100.0
C16	Stomach	6	28.6	7	33.3	8	38.1	-	-	-	-	-	-	21	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C18	Colon	10	45.5	4	18.2	8	36.4	-	-	-	-	-	-	22	100.0
C19-20	Rectum	31	32.6	35	36.8	29	30.5	-	-	-	-	-	-	95	100.0
C21	Anus & Anal Canal	1	50.0	1	50.0	-	-	-	-	-	-	-	-	2	100.0
C22	Liver	1	25.0	1	25.0	2	50.0	-	-	-	-	-	-	4	100.0
C23-24	Gallbladder etc.	1	25.0	-	-	3	75.0	-	-	-	-	-	-	4	100.0
C25	Pancreas	-	-	2	40.0	3	60.0	-	-	-	-	-	-	5	100.0
C30-31	Nose, Sinuses etc.	-	-	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C32	Larynx	1	25.0	3	75.0	-	-	-	-	-	-	-	-	4	100.0
C33-34	Lung etc.	-	-	25	54.3	21	45.7	-	-	-	-	-	-	46	100.0
C37-38	Other Thoracic Organs	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C40-41	Bone	4	57.1	-	-	3	42.9	-	-	-	-	-	-	7	100.0
C43	Melanoma of Skin	11	78.6	2	14.3	1	7.1	-	-	-	-	-	-	14	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	5	41.7	5	41.7	2	16.7	-	-	-	-	-	-	12	100.0
C50	Breast	264	26.3	224	22.3	259	25.8	258	25.7	-	-	-	-	1005	100.0
C51	Vulva	1	33.3	2	66.7	-	-	-	-	-	-	-	-	3	100.0
C52	Vagina	-	-	5	62.5	3	37.5	-	-	-	-	-	-	8	100.0
C53	Cervix Uteri	11	6.4	94	54.7	67	39.0	-	-	-	-	-	-	172	100.0
C54	Corpus Uteri	21	46.7	16	35.6	8	17.8	-	-	-	-	-	-	45	100.0
C55	Uterus Unspecified	-	-	-	-	3	100.0	-	-	-	-	-	-	3	100.0
C56	Ovary etc.	36	48.0	1	1.3	38	50.7	-	-	-	-	-	-	75	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C67	Bladder	4	80.0	1	20.0	-	-	-	-	-	-	-	-	5	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	33.3	1	33.3	1	33.3	-	-	-	-	-	-	3	100.0
C70-72	Brain, Nervous System	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	14	70.0	6	30.0	-	-	-	-	-	-	-	-	20	100.0
C74	Adrenal Gland	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	-	-	1	9.1	10	90.9	-	-	-	-	-	-	11	100.0
C82-85,C96	NHL	-	-	9	24.3	28	75.7	-	-	-	-	-	-	37	100.0
C88	Malig Imn.Prol D	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	-	-	6	17.1	29	82.9	-	-	-	-	-	-	35	100.0
C91	Lymphoid Leuk.	-	-	-	-	6	100.0	-	-	-	-	-	-	6	100.0
C92-94	Myeloid Leukaemia	-	-	1	5.3	17	89.5	-	-	1	5.3	-	-	19	100.0
C95	Leukaemia Uns	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	-	-	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
	<b>All Sites</b>	<b>486</b>	<b>25.6</b>	<b>564</b>	<b>29.7</b>	<b>589</b>	<b>31.0</b>	<b>258</b>	<b>13.6</b>	<b>1</b>	<b>0.1</b>	-	-	<b>1898</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 10(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) - Males**

As on: 29/06/2020

ICD 10	Site	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C01-02	Tongue	89	78.1	7	6.1	16	14.0	2	1.8	-	-	114	100.0
C03-06	Mouth	97	74.0	11	8.4	18	13.7	5	3.8	-	-	131	100.0
C07-08	Salivary Gland	1	20.0	3	60.0	1	20.0	-	-	-	-	5	100.0
C09	Tonsil	10	83.3	2	16.7	-	-	-	-	-	-	12	100.0
C10	Oth. Oropharynx	38	65.5	6	10.3	14	24.1	-	-	-	-	58	100.0
C11	Nasopharynx	8	80.0	-	-	1	10.0	1	10.0	-	-	10	100.0
C12-13	Hypopharynx	30	71.4	5	11.9	6	14.3	1	2.4	-	-	42	100.0
C14	Pharynx Unspecified	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C15	Oesophagus	39	49.4	26	32.9	11	13.9	3	3.8	-	-	79	100.0
C16	Stomach	53	41.7	48	37.8	24	18.9	2	1.6	-	-	127	100.0
C17	Small Intestine	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C18	Colon	17	50.0	16	47.1	1	2.9	-	-	-	-	34	100.0
C19-20	Rectum	63	71.6	18	20.5	5	5.7	2	2.3	-	-	88	100.0
C21	Anus & Anal Canal	6	66.7	2	22.2	-	-	1	11.1	-	-	9	100.0
C22	Liver	9	15.3	42	71.2	6	10.2	2	3.4	-	-	59	100.0
C23-24	Gallbladder etc.	2	20.0	5	50.0	3	30.0	-	-	-	-	10	100.0
C25	Pancreas	11	31.4	20	57.1	2	5.7	2	5.7	-	-	35	100.0
C30-31	Nose, Sinuses etc.	3	50.0	-	-	1	16.7	2	33.3	-	-	6	100.0
C32	Larynx	71	74.0	8	8.3	14	14.6	3	3.1	-	-	96	100.0
C33-34	Lung etc.	213	45.5	180	38.5	55	11.8	20	4.3	-	-	468	100.0
C37-38	Other Thoracic Organs	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C40-41	Bone	7	70.0	2	20.0	1	10.0	-	-	-	-	10	100.0
C43	Melanoma of Skin	17	70.8	5	20.8	2	8.3	-	-	-	-	24	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	11	84.6	2	15.4	-	-	-	-	-	-	13	100.0
C50	Breast	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	4	66.7	1	16.7	1	16.7	-	-	-	-	6	100.0
C61	Prostate	29	59.2	12	24.5	6	12.2	2	4.1	-	-	49	100.0
C62	Testis	2	66.7	-	-	-	-	1	33.3	-	-	3	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	6	35.3	9	52.9	2	11.8	-	-	-	-	17	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	12	46.2	11	42.3	3	11.5	-	-	-	-	26	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	1	16.7	3	50.0	2	33.3	-	-	-	-	6	100.0
C73	Thyroid	4	66.7	1	16.7	1	16.7	-	-	-	-	6	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	9	69.2	4	30.8	-	-	-	-	-	-	13	100.0
C82-85,C96	NHL	47	46.1	39	38.2	4	3.9	12	11.8	-	-	102	100.0
C88	Malig Imm.Prol D	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	24	61.5	7	17.9	2	5.1	6	15.4	-	-	39	100.0
C91	Lymphoid Leuk.	6	35.3	10	58.8	-	-	1	5.9	-	-	17	100.0
C92-94	Myeloid Leukaemia	26	53.1	12	24.5	2	4.1	9	18.4	-	-	49	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	19	26.4	43	59.7	9	12.5	1	1.4	-	-	72	100.0
	<b>All Sites</b>	<b>990</b>	<b>53.7</b>	<b>564</b>	<b>30.6</b>	<b>213</b>	<b>11.5</b>	<b>78</b>	<b>4.2</b>	<b>-</b>	<b>-</b>	<b>1845</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 10(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) - Females**

As on: 29/06/2020

ICD 10	Site	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	5	71.4	-	-	1	14.3	1	14.3	-	-	7	100.0
C01-02	Tongue	33	80.5	4	9.8	4	9.8	-	-	-	-	41	100.0
C03-06	Mouth	69	75.0	11	12.0	7	7.6	5	5.4	-	-	92	100.0
C07-08	Salivary Gland	5	83.3	-	-	1	16.7	-	-	-	-	6	100.0
C09	Tonsil	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	1	33.3	1	33.3	1	33.3	-	-	-	-	3	100.0
C11	Nasopharynx	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C12-13	Hypopharynx	10	100.0	-	-	-	-	-	-	-	-	10	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	18	54.5	10	30.3	5	15.2	-	-	-	-	33	100.0
C16	Stomach	17	34.0	25	50.0	8	16.0	-	-	-	-	50	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	-	-
C18	Colon	17	60.7	8	28.6	2	7.1	1	3.6	-	-	28	100.0
C19-20	Rectum	43	67.2	12	18.8	9	14.1	-	-	-	-	64	100.0
C21	Anus & Anal Canal	2	66.7	-	-	1	33.3	-	-	-	-	3	100.0
C22	Liver	3	21.4	9	64.3	1	7.1	1	7.1	-	-	14	100.0
C23-24	Gallbladder etc.	3	21.4	10	71.4	1	7.1	-	-	-	-	14	100.0
C25	Pancreas	5	29.4	7	41.2	3	17.6	2	11.8	-	-	17	100.0
C30-31	Nose, Sinuses etc.	2	50.0	-	-	2	50.0	-	-	-	-	4	100.0
C32	Larynx	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C33-34	Lung etc.	35	40.2	39	44.8	9	10.3	4	4.6	-	-	87	100.0
C37-38	Other Thoracic Organs	1	50.0	-	-	-	-	1	50.0	-	-	2	100.0
C40-41	Bone	5	62.5	2	25.0	-	-	1	12.5	-	-	8	100.0
C43	Melanoma of Skin	14	66.7	7	33.3	-	-	-	-	-	-	21	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	8	72.7	2	18.2	1	9.1	-	-	-	-	11	100.0
C50	Breast	332	77.8	46	10.8	27	6.3	22	5.2	-	-	427	100.0
C51	Vulva	3	75.0	-	-	1	25.0	-	-	-	-	4	100.0
C52	Vagina	5	71.4	1	14.3	1	14.3	-	-	-	-	7	100.0
C53	Cervix Uteri	99	78.0	10	7.9	15	11.8	3	2.4	-	-	127	100.0
C54	Corpus Uteri	25	67.6	11	29.7	1	2.7	-	-	-	-	37	100.0
C55	Uterus Unspecified	3	75.0	-	-	-	-	1	25.0	-	-	4	100.0
C56	Ovary etc.	46	56.1	26	31.7	8	9.8	2	2.4	-	-	82	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	2	50.0	2	50.0	-	-	-	-	-	-	4	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	5	62.5	1	12.5	2	25.0	-	-	-	-	8	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C73	Thyroid	20	48.8	12	29.3	9	22.0	-	-	-	-	41	100.0
C74	Adrenal Gland	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	10	83.3	1	8.3	-	-	1	8.3	-	-	12	100.0
C82-85, C96	NHL	29	48.3	19	31.7	2	3.3	10	16.7	-	-	60	100.0
C88	Malig Imn. Prol D	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	29	52.7	9	16.4	3	5.5	14	25.5	-	-	55	100.0
C91	Lymphoid Leuk.	6	30.0	11	55.0	1	5.0	2	10.0	-	-	20	100.0
C92-94	Myeloid Leukaemia	18	47.4	12	31.6	2	5.3	6	15.8	-	-	38	100.0
C95	Leukaemia Uns	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
O&U	Other and Uns	2	9.5	18	85.7	1	4.8	-	-	-	-	21	100.0
	<b>All Sites</b>	<b>942</b>	<b>63.6</b>	<b>332</b>	<b>22.4</b>	<b>129</b>	<b>8.7</b>	<b>77</b>	<b>5.2</b>	<b>-</b>	<b>-</b>	<b>1480</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 11 (a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Intention to Treat at Reporting Institution (Excluding the Cancers Previously Treated) – Males**

As on: 29/06/2020

ICD 10	Site	Radical		Palliative		Pain Relief Only		Symptomatic		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-
C01-02	Tongue	70	78.7	19	21.3	-	-	-	-	-	-	89	100.0
C03-06	Mouth	63	64.9	34	35.1	-	-	-	-	-	-	97	100.0
C07-08	Salivary Gland	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C09	Tonsil	6	60.0	4	40.0	-	-	-	-	-	-	10	100.0
C10	Oth. Oropharynx	24	63.2	14	36.8	-	-	-	-	-	-	38	100.0
C11	Nasopharynx	4	50.0	4	50.0	-	-	-	-	-	-	8	100.0
C12-13	Hypopharynx	14	46.7	16	53.3	-	-	-	-	-	-	30	100.0
C14	Pharynx Unspecified	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C15	Oesophagus	10	25.6	28	71.8	-	-	1	2.6	-	-	39	100.0
C16	Stomach	20	37.7	33	62.3	-	-	-	-	-	-	53	100.0
C17	Small Intestine	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C18	Colon	10	58.8	7	41.2	-	-	-	-	-	-	17	100.0
C19-20	Rectum	47	74.6	16	25.4	-	-	-	-	-	-	63	100.0
C21	Anus & Anal Canal	2	33.3	4	66.7	-	-	-	-	-	-	6	100.0
C22	Liver	2	22.2	7	77.8	-	-	-	-	-	-	9	100.0
C23-24	Gallbladder etc.	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C25	Pancreas	1	9.1	9	81.8	-	-	1	9.1	-	-	11	100.0
C30-31	Nose, Sinuses etc.	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C32	Larynx	54	76.1	17	23.9	-	-	-	-	-	-	71	100.0
C33-34	Lung etc.	36	16.9	177	83.1	-	-	-	-	-	-	213	100.0
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	-	-	-
C40-41	Bone	6	85.7	1	14.3	-	-	-	-	-	-	7	100.0
C43	Melanoma of Skin	14	82.4	3	17.6	-	-	-	-	-	-	17	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	5	45.5	6	54.5	-	-	-	-	-	-	11	100.0
C50	Breast	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C61	Prostate	18	62.1	10	34.5	-	-	1	3.4	-	-	29	100.0
C62	Testis	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C63	Other Male Genital	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	3	50.0	3	50.0	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	8	66.7	4	33.3	-	-	-	-	-	-	12	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C73	Thyroid	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	6	66.7	3	33.3	-	-	-	-	-	-	9	100.0
C82-85,C96	NHL	23	48.9	23	48.9	-	-	1	2.1	-	-	47	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	11	45.8	13	54.2	-	-	-	-	-	-	24	100.0
C91	Lymphoid Leuk.	4	66.7	2	33.3	-	-	-	-	-	-	6	100.0
C92-94	Myeloid Leukaemia	11	42.3	14	53.8	1	3.8	-	-	-	-	26	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	2	10.5	17	89.5	-	-	-	-	-	-	19	100.0
	<b>All Sites</b>	<b>488</b>	<b>49.3</b>	<b>497</b>	<b>50.2</b>	<b>1</b>	<b>0.1</b>	<b>4</b>	<b>0.4</b>	<b>-</b>	<b>-</b>	<b>990</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 11 (b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Intention to Treat at Reporting Institution (Excluding the Cancers Previously Treated) – Females**

As on: 29/06/2020

ICD 10	Site	Radical		Palliative		Pain Relief Only		Symptomatic		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	20.0	4	80.0	-	-	-	-	-	-	5	100.0
C01-02	Tongue	24	72.7	9	27.3	-	-	-	-	-	-	33	100.0
C03-06	Mouth	33	47.8	36	52.2	-	-	-	-	-	-	69	100.0
C07-08	Salivary Gland	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C09	Tonsil	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C11	Nasopharynx	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	6	60.0	4	40.0	-	-	-	-	-	-	10	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	6	33.3	12	66.7	-	-	-	-	-	-	18	100.0
C16	Stomach	8	47.1	9	52.9	-	-	-	-	-	-	17	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	-	-
C18	Colon	8	47.1	8	47.1	-	-	1	5.9	-	-	17	100.0
C19-20	Rectum	33	76.7	10	23.3	-	-	-	-	-	-	43	100.0
C21	Anus & Anal Canal	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C22	Liver	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C23-24	Gallbladder etc.	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C25	Pancreas	-	-	5	100.0	-	-	-	-	-	-	5	100.0
C30-31	Nose, Sinuses etc.	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C32	Larynx	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C33-34	Lung etc.	5	14.3	29	82.9	-	-	1	2.9	-	-	35	100.0
C37-38	Other Thoracic Organs	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C40-41	Bone	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C43	Melanoma of Skin	11	78.6	3	21.4	-	-	-	-	-	-	14	100.0
C44	Other Skin	-	-	-	-	-	-	-	-	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	6	75.0	2	25.0	-	-	-	-	-	-	8	100.0
C50	Breast	277	83.4	55	16.6	-	-	-	-	-	-	332	100.0
C51	Vulva	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C52	Vagina	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C53	Cervix Uteri	76	76.8	23	23.2	-	-	-	-	-	-	99	100.0
C54	Corpus Uteri	23	92.0	2	8.0	-	-	-	-	-	-	25	100.0
C55	Uterus Unspecified	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C56	Ovary etc.	33	71.7	13	28.3	-	-	-	-	-	-	46	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	13	65.0	7	35.0	-	-	-	-	-	-	20	100.0
C74	Adrenal Gland	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	3	30.0	7	70.0	-	-	-	-	-	-	10	100.0
C82-85,C96	NHL	13	44.8	16	55.2	-	-	-	-	-	-	29	100.0
C88	Malig Imn.Prol D	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	6	20.7	23	79.3	-	-	-	-	-	-	29	100.0
C91	Lymphoid Leuk.	4	66.7	2	33.3	-	-	-	-	-	-	6	100.0
C92-94	Myeloid Leukaemia	7	38.9	11	61.1	-	-	-	-	-	-	18	100.0
C95	Leukaemia Uns	1	100.0	-	-	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
	<b>All Sites</b>	<b>630</b>	<b>66.9</b>	<b>310</b>	<b>32.9</b>	-	-	<b>2</b>	<b>0.2</b>	-	-	<b>942</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97



**Table 12(a): Number (#) and Proportion(%) of cancers by site (ICD-10) and Marital Status  
- Males**

ICD 10	Site	Unmarried		Married		Widowed		Divorced		Separated		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C01-02	Tongue	1	0.7	141	99.3	-	-	-	-	-	-	-	-	-	-	142	100.0
C03-06	Mouth	6	3.5	165	95.9	1	0.6	-	-	-	-	-	-	-	-	172	100.0
C07-08	Salivary Gland	-	-	7	100.0	-	-	-	-	-	-	-	-	-	-	7	100.0
C09	Tonsil	1	8.3	10	83.3	1	8.3	-	-	-	-	-	-	-	-	12	100.0
C10	Oth. Oropharynx	-	-	62	96.9	2	3.1	-	-	-	-	-	-	-	-	64	100.0
C11	Nasopharynx	2	15.4	11	84.6	-	-	-	-	-	-	-	-	-	-	13	100.0
C12-13	Hypopharynx	1	1.9	52	96.3	1	1.9	-	-	-	-	-	-	-	-	54	100.0
C14	Pharynx Unspecified	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C15	Oesophagus	1	1.2	81	95.3	3	3.5	-	-	-	-	1	-	-	-	85	100.0
C16	Stomach	2	1.1	176	97.8	2	1.1	-	-	-	-	-	-	-	-	180	100.0
C17	Small Intestine	-	-	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C18	Colon	3	4.6	62	95.4	-	-	-	-	-	-	-	-	-	-	65	100.0
C19-20	Rectum	7	5.6	115	92.7	1	0.8	1	0.8	-	-	-	-	-	-	124	100.0
C21	Anus & Anal Canal	-	-	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C22	Liver	1	1.3	76	98.7	-	-	-	-	-	-	1	-	-	-	77	100.0
C23-24	Gallbladder etc.	1	6.7	14	93.3	-	-	-	-	-	-	-	-	-	-	15	100.0
C25	Pancreas	2	4.7	39	90.7	2	4.7	-	-	-	-	-	-	-	-	43	100.0
C30-31	Nose, Sinuses etc.	-	-	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C32	Larynx	2	1.7	117	96.7	1	0.8	1	0.8	-	-	-	-	-	-	121	100.0
C33-34	Lung etc.	11	2.1	504	96.7	4	0.8	1	0.2	-	-	-	1	0.2	-	521	100.0
C37-38	Other Thoracic Organs	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	6	42.9	8	57.1	-	-	-	-	-	-	-	-	-	-	14	100.0
C43	Melanoma of Skin	1	2.4	40	97.6	-	-	-	-	-	-	-	-	-	-	41	100.0
C44	Other Skin	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	7	28.0	17	68.0	-	-	1	4.0	-	-	-	-	-	-	25	100.0
C50	Breast	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C61	Prostate	1	0.9	103	96.3	3	2.8	-	-	-	-	-	-	-	-	107	100.0
C62	Testis	3	37.5	5	62.5	-	-	-	-	-	-	-	-	-	-	8	100.0
C63	Other Male Genital	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C64	Kidney etc.	-	-	29	100.0	-	-	-	-	-	-	-	-	-	-	29	100.0
C65	Renal Pelvis	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	1.7	57	95.0	2	3.3	-	-	-	-	-	-	-	-	60	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	3	7.5	37	92.5	-	-	-	-	-	-	-	-	-	-	40	100.0
C73	Thyroid	2	9.5	19	90.5	-	-	-	-	-	-	-	-	-	-	21	100.0
C74	Adrenal Gland	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C81	Hodgkins Disease	6	30.0	14	70.0	-	-	-	-	-	-	-	-	-	-	20	100.0
C82-85,C96	NHL	13	10.1	114	88.4	2	1.6	-	-	-	-	-	-	-	-	129	100.0
C88	Malig Imn.Prol D	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C90	Multiple Myeloma	1	2.1	46	95.8	1	2.1	-	-	-	-	-	-	-	-	48	100.0
C91	Lymphoid Leuk.	7	35.0	12	60.0	1	5.0	-	-	-	-	-	-	-	-	20	100.0
C92-94	Myeloid Leukaemia	6	10.2	53	89.8	-	-	-	-	-	-	-	-	-	-	59	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	3	3.8	71	88.8	4	5.0	2	2.5	-	-	-	-	-	-	80	100.0
	All Sites	103	4.2	2306	94.2	31	1.3	6	0.2	-	-	-	-	1	0.0	2447	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 12(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Marital Status - Females**

ICD 10	Site	Unmarried		Married		Widowed		Divorced		Separated		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	6	54.5	4	36.4	1	9.1	-	-	-	-	-	-	11	100.0
C01-02	Tongue	1	1.8	39	68.4	16	28.1	1	1.8	-	-	-	-	-	-	57	100.0
C03-06	Mouth	2	1.8	58	52.7	48	43.6	2	1.8	-	-	-	-	-	-	110	100.0
C07-08	Salivary Gland	4	26.7	8	53.3	3	20.0	-	-	-	-	-	-	-	-	15	100.0
C09	Tonsil	-	-	1	33.3	1	33.3	1	33.3	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	-	-	2	50.0	2	50.0	-	-	-	-	-	-	-	-	4	100.0
C11	Nasopharynx	-	-	2	50.0	2	50.0	-	-	-	-	-	-	-	-	4	100.0
C12-13	Hypopharynx	1	9.1	8	72.7	2	18.2	-	-	-	-	-	-	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	2	5.0	24	60.0	12	30.0	2	5.0	-	-	-	-	-	-	40	100.0
C16	Stomach	3	4.7	38	59.4	23	35.9	-	-	-	-	-	-	-	-	64	100.0
C17	Small Intestine	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	-	-	41	77.4	12	22.6	-	-	-	-	-	-	-	-	53	100.0
C19-20	Rectum	1	1.1	64	70.3	25	27.5	1	1.1	-	-	-	-	-	-	91	100.0
C21	Anus & Anal Canal	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	2	9.1	14	63.6	2	9.1	3	13.6	-	-	1	4.5	-	-	22	100.0
C23-24	Gallbladder etc.	1	4.8	10	47.6	10	47.6	-	-	-	-	-	-	-	-	21	100.0
C25	Pancreas	-	-	22	75.9	6	20.7	1	3.4	-	-	-	-	-	-	29	100.0
C30-31	Nose, Sinuses etc.	-	-	3	75.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C32	Larynx	-	-	4	80.0	1	20.0	-	-	-	-	-	-	-	-	5	100.0
C33-34	Lung etc.	3	2.9	84	80.8	16	15.4	1	1.0	-	-	-	-	-	-	104	100.0
C37-38	Other Thoracic Organs	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C40-41	Bone	6	60.0	2	20.0	2	20.0	-	-	-	-	-	-	-	-	10	100.0
C43	Melanoma of Skin	-	-	25	69.4	11	30.6	-	-	-	-	-	-	-	-	36	100.0
C44	Other Skin	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	5	18.5	18	66.7	4	14.8	-	-	-	-	-	-	-	-	27	100.0
C50	Breast	35	5.3	515	78.6	95	14.5	10	1.5	-	-	-	-	-	-	655	100.0
C51	Vulva	-	-	5	83.3	1	16.7	-	-	-	-	-	-	-	-	6	100.0
C52	Vagina	-	-	2	22.2	7	77.8	-	-	-	-	-	-	-	-	9	100.0
C53	Cervix Uteri	2	1.3	108	68.8	41	26.1	6	3.8	-	-	-	-	-	-	157	100.0
C54	Corpus Uteri	6	6.7	69	77.5	11	12.4	2	2.2	-	-	-	-	1	1.1	89	100.0
C55	Uterus Unspecified	-	-	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C56	Ovary etc.	8	6.0	98	73.1	24	17.9	4	3.0	-	-	-	-	-	-	134	100.0
C57	Other Female Genital	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	-	-	3	50.0	3	50.0	-	-	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	-	-	11	78.6	3	21.4	-	-	-	-	-	-	-	-	14	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	5	14.3	25	71.4	4	11.4	1	2.9	-	-	-	-	-	-	35	100.0
C73	Thyroid	3	3.8	60	76.9	15	19.2	-	-	-	-	-	-	-	-	78	100.0
C74	Adrenal Gland	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	2	12.5	12	75.0	1	6.2	1	6.2	-	-	-	-	-	-	16	100.0
C82-85,C96	NHL	3	4.2	53	74.6	15	21.1	-	-	-	-	-	-	-	-	71	100.0
C88	Malig Imn.Prol D	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	2	2.9	47	68.1	20	29.0	-	-	-	-	-	-	-	-	69	100.0
C91	Lymphoid Leuk.	7	29.2	14	58.3	3	12.5	-	-	-	-	-	-	-	-	24	100.0
C92-94	Myeloid Leukaemia	6	12.5	40	83.3	2	4.2	-	-	-	-	-	-	-	-	48	100.0
C95	Leukaemia Uns	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	2	100.0
O&U	Other and Uns	3	13.0	13	56.5	7	30.4	-	-	-	-	-	-	-	-	23	100.0
	All Sites	114	5.2	1570	72.0	457	21.0	37	1.7	-	-	1	0.0	1	0.0	2180	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 13(a): Number (#) and Proportion(%) of cancers by site (ICD-10) and Religion - Males**

ICD 10	Site	Hindu		Muslim		Christian		Neo-Budhist		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C01-02	Tongue	98	69.0	32	22.5	12	8.5	-	-	-	-	-	-	142	100.0
C03-06	Mouth	104	60.5	41	23.8	27	15.7	-	-	-	-	-	-	172	100.0
C07-08	Salivary Gland	4	57.1	2	28.6	1	14.3	-	-	-	-	-	-	7	100.0
C09	Tonsil	7	58.3	1	8.3	4	33.3	-	-	-	-	-	-	12	100.0
C10	Oth. Oropharynx	54	84.4	6	9.4	4	6.2	-	-	-	-	-	-	64	100.0
C11	Nasopharynx	5	38.5	5	38.5	3	23.1	-	-	-	-	-	-	13	100.0
C12-13	Hypopharynx	39	72.2	7	13.0	8	14.8	-	-	-	-	-	-	54	100.0
C14	Pharynx Unspecified	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C15	Oesophagus	60	70.6	12	14.1	13	15.3	-	-	-	-	-	-	85	100.0
C16	Stomach	121	67.2	47	26.1	12	6.7	-	-	-	-	-	-	180	100.0
C17	Small Intestine	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C18	Colon	38	58.5	20	30.8	7	10.8	-	-	-	-	-	-	65	100.0
C19-20	Rectum	75	60.5	31	25.0	18	14.5	-	-	-	-	-	-	124	100.0
C21	Anus & Anal Canal	5	55.6	3	33.3	1	11.1	-	-	-	-	-	-	9	100.0
C22	Liver	49	63.6	20	26.0	8	10.4	-	-	-	-	-	-	77	100.0
C23-24	Gallbladder etc.	7	46.7	6	40.0	2	13.3	-	-	-	-	-	-	15	100.0
C25	Pancreas	19	44.2	17	39.5	7	16.3	-	-	-	-	-	-	43	100.0
C30-31	Nose, Sinuses etc.	7	77.8	2	22.2	-	-	-	-	-	-	-	-	9	100.0
C32	Larynx	81	66.9	27	22.3	13	10.7	-	-	-	-	-	-	121	100.0
C33-34	Lung etc.	292	56.0	176	33.8	52	10.0	1	0.2	-	-	-	-	521	100.0
C37-38	Other Thoracic Organs	1	50.0	1	50.0	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	6	42.9	5	35.7	3	21.4	-	-	-	-	-	-	14	100.0
C43	Melanoma of Skin	22	53.7	16	39.0	3	7.3	-	-	-	-	-	-	41	100.0
C44	Other Skin	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	12	48.0	12	48.0	1	4.0	-	-	-	-	-	-	25	100.0
C50	Breast	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C61	Prostate	68	63.6	28	26.2	11	10.3	-	-	-	-	-	-	107	100.0
C62	Testis	4	50.0	1	12.5	3	37.5	-	-	-	-	-	-	8	100.0
C63	Other Male Genital	-	-	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C64	Kidney etc.	17	58.6	12	41.4	-	-	-	-	-	-	-	-	29	100.0
C65	Renal Pelvis	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	24	40.0	29	48.3	7	11.7	-	-	-	-	-	-	60	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	18	45.0	17	42.5	5	12.5	-	-	-	-	-	-	40	100.0
C73	Thyroid	15	71.4	3	14.3	3	14.3	-	-	-	-	-	-	21	100.0
C74	Adrenal Gland	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C81	Hodgkins Disease	9	45.0	11	55.0	-	-	-	-	-	-	-	-	20	100.0
C82-85,C96	NHL	86	66.7	32	24.8	11	8.5	-	-	-	-	-	-	129	100.0
C88	Malig Imn.Prol D	1	50.0	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C90	Multiple Myeloma	31	64.6	10	20.8	7	14.6	-	-	-	-	-	-	48	100.0
C91	Lymphoid Leuk.	9	45.0	10	50.0	1	5.0	-	-	-	-	-	-	20	100.0
C92-94	Myeloid Leukaemia	34	57.6	19	32.2	6	10.2	-	-	-	-	-	-	59	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	52	65.0	20	25.0	8	10.0	-	-	-	-	-	-	80	100.0
	<b>All Sites</b>	<b>1497</b>	<b>61.2</b>	<b>686</b>	<b>28.0</b>	<b>263</b>	<b>10.7</b>	<b>1</b>	<b>0.0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2447</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 13(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion - Females**

ICD 10	Site	Hindu		Muslim		Christian		Neo-Budhist		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	9	81.8	2	18.2	-	-	-	-	-	-	-	-	11	100.0
C01-02	Tongue	35	61.4	20	35.1	2	3.5	-	-	-	-	-	-	57	100.0
C03-06	Mouth	70	63.6	36	32.7	3	2.7	-	-	-	-	1	0.9	110	100.0
C07-08	Salivary Gland	10	66.7	5	33.3	-	-	-	-	-	-	-	-	15	100.0
C09	Tonsil	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	3	75.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C11	Nasopharynx	3	75.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C12-13	Hypopharynx	8	72.7	2	18.2	-	-	1	9.1	-	-	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	23	57.5	14	35.0	3	7.5	-	-	-	-	-	-	40	100.0
C16	Stomach	35	54.7	25	39.1	4	6.2	-	-	-	-	-	-	64	100.0
C17	Small Intestine	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	40	75.5	9	17.0	4	7.5	-	-	-	-	-	-	53	100.0
C19-20	Rectum	60	65.9	26	28.6	5	5.5	-	-	-	-	-	-	91	100.0
C21	Anus & Anal Canal	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	16	72.7	5	22.7	1	4.5	-	-	-	-	-	-	22	100.0
C23-24	Gallbladder etc.	15	71.4	4	19.0	2	9.5	-	-	-	-	-	-	21	100.0
C25	Pancreas	16	55.2	9	31.0	4	13.8	-	-	-	-	-	-	29	100.0
C30-31	Nose, Sinuses etc.	3	75.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C32	Larynx	2	40.0	3	60.0	-	-	-	-	-	-	-	-	5	100.0
C33-34	Lung etc.	60	57.7	35	33.7	9	8.7	-	-	-	-	-	-	104	100.0
C37-38	Other Thoracic Organs	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C40-41	Bone	7	70.0	3	30.0	-	-	-	-	-	-	-	-	10	100.0
C43	Melanoma of Skin	19	52.8	14	38.9	3	8.3	-	-	-	-	-	-	36	100.0
C44	Other Skin	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	9	33.3	17	63.0	1	3.7	-	-	-	-	-	-	27	100.0
C50	Breast	396	60.5	182	27.8	76	11.6	-	-	-	-	1	0.2	655	100.0
C51	Vulva	4	66.7	2	33.3	-	-	-	-	-	-	-	-	6	100.0
C52	Vagina	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C53	Cervix Uteri	107	68.2	36	22.9	14	8.9	-	-	-	-	-	-	157	100.0
C54	Corpus Uteri	56	62.9	24	27.0	9	10.1	-	-	-	-	-	-	89	100.0
C55	Uterus Unspecified	5	55.6	4	44.4	-	-	-	-	-	-	-	-	9	100.0
C56	Ovary etc.	77	57.5	41	30.6	16	11.9	-	-	-	-	-	-	134	100.0
C57	Other Female Genital	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	1	16.7	2	33.3	3	50.0	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	9	64.3	4	28.6	1	7.1	-	-	-	-	-	-	14	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	20	57.1	14	40.0	1	2.9	-	-	-	-	-	-	35	100.0
C73	Thyroid	48	61.5	23	29.5	7	9.0	-	-	-	-	-	-	78	100.0
C74	Adrenal Gland	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	12	75.0	2	12.5	2	12.5	-	-	-	-	-	-	16	100.0
C82-85,C96	NHL	38	53.5	25	35.2	8	11.3	-	-	-	-	-	-	71	100.0
C88	Malig Imn.Prol D	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	43	62.3	19	27.5	7	10.1	-	-	-	-	-	-	69	100.0
C91	Lymphoid Leuk.	16	66.7	7	29.2	1	4.2	-	-	-	-	-	-	24	100.0
C92-94	Myeloid Leukaemia	28	58.3	15	31.2	5	10.4	-	-	-	-	-	-	48	100.0
C95	Leukaemia Uns	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
O&U	Other and Uns	13	56.5	9	39.1	1	4.3	-	-	-	-	-	-	23	100.0
	<b>All Sites</b>	<b>1341</b>	<b>61.5</b>	<b>643</b>	<b>29.5</b>	<b>193</b>	<b>8.9</b>	<b>1</b>	<b>0.0</b>	-	-	<b>2</b>	<b>0.1</b>	<b>2180</b>	<b>100.0</b>

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97







**DETAILED  
INFORMATION-MCC**



**Table 1: Number of New and Old Cancer Cases**

sex	Old		New		Total
	#	%	#	%	
Female	700	32.1%	1480	67.9%	2180
Male	602	24.6%	1845	75.4%	2447

**Table 2: Number and Proportion of System wise & Sex wise Cancer Incidence**

System	Male	%	Female	%	Total
Head & Neck	626	66.5%	316	33.5%	942
Digestive Organs	610	65.0%	328	35.0%	938
Breast	2	0.3%	655	99.7%	657
Respiratory system	521	83.4%	104	16.6%	625
Hematological and RE System	264	54.9%	217	45.1%	481
Gynecological system	....	....	406	100.0%	406
Male genital organ	126	100.0%	....	....	126
Urinary tract	90	81.1%	21	18.9%	111
Primary unknown	79	78.2%	22	21.8%	101
CNS	41	53.2%	36	46.8%	77
skin	41	56.2%	32	43.8%	73
Soft tissue system	25	49.0%	26	51.0%	51
skeletal-bones etc	17	58.6%	12	41.4%	29
Intrathoracic organs	2	40.0%	3	60.0%	5
Endocrine glands	3	75.0%	1	25.0%	4
Peripheral nervous system	....	....	1	100.0%	1

**Table 3: Number (#) and Proportion of System wise& Alcohol Habit**

System wise Alcohol Habit							
	No Habit	%	Habit	%	Unknown	%	Total
Head & Neck	526	55.8%	368	39.1%	48	5.1%	942
Digestive Organs	635	67.7%	273	29.1%	30	3.2%	938
Breast	611	93.0%	3	0.5%	41	6.2%	657
Respiratory system	376	60.2%	235	37.6%	14	2.2%	625
Hematological and RE System	370	76.9%	93	19.3%	17	3.5%	481
Gynecological system	388	95.6%	0	0.0%	18	4.4%	406
Male genital organ	78	61.9%	45	35.7%	3	2.4%	126
Urinary tract	78	70.3%	29	26.1%	3	2.7%	111
Primary unknown	63	62.4%	33	32.7%	5	5.0%	101
CNS	58	75.3%	14	18.2%	5	6.5%	77

skin	60	82.2%	9	12.3%	4	5.5%	73
Soft tissue system	46	90.2%	3	5.9%	2	3.9%	51
skeletal-bones etc	22	75.9%	5	17.2%	2	6.9%	29
Intrathoracic organs	3	60.0%	1	20.0%	1	20.0%	5
Endocrine glands	3	75.0%	1	25.0%	0	0.0%	4
Peripheral nervous system	1	100.0%	0	0.0%	0	0.0%	1

**Table 4: Number (#) and Proportion of System Wise & Pan chewing Habit**

<b>System wise Pan chewing habit</b>							
	No habit	%	Habit	%	Un-known	%	Total
Head & Neck	553	58.7%	341	36.2%	47	5.0%	942
Digestive Organs	753	80.3%	157	16.7%	28	3.0%	938
Breast	573	87.2%	44	6.7%	39	5.9%	657
Respiratory system	505	80.8%	105	16.8%	14	2.2%	625
Hematological and RE System	409	85.0%	54	11.2%	17	3.5%	481
Gynecological system	342	84.2%	47	11.6%	15	3.7%	406
Male genital organ	100	79.4%	22	17.5%	4	3.2%	126
Urinary tract	88	79.3%	18	16.2%	4	3.6%	111
Primary unknown	83	82.2%	14	13.9%	4	4.0%	101
CNS	60	77.9%	11	14.3%	6	7.8%	77
skin	57	78.1%	12	16.4%	4	5.5%	73
Soft tissue system	42	82.4%	7	13.7%	2	3.9%	51
skeletal-bones etc	22	75.9%	5	17.2%	2	6.9%	29
Intrathoracic organs	3	60.0%	1	20.0%	1	20.0%	5
Endocrine glands	4	100.0%	0	0.0%	0	0.0%	4
Peripheral nervous system	1	100.0%	0	0.0%	0	0.0%	1

**Table 5: Number (#) and Proportion of System Wise Smoking Habit**

<b>System wise Smoking Habit</b>							
	No Habit	%	Habit	%	Un-known	%	Total
Head & Neck	486	51.6%	411	43.6%	45	4.8%	942
Digestive Organs	562	59.9%	347	37.0%	29	3.1%	938
Breast	616	93.8%	1	0.2%	39	5.9%	657
Respiratory system	192	30.7%	419	67.0%	14	2.2%	625
Hematological and RE System	360	74.8%	102	21.2%	18	3.7%	481
Gynecological system	388	95.6%	1	0.2%	17	4.2%	406
Male genital organ	56	44.4%	67	53.2%	3	2.4%	126
Urinary tract	44	39.6%	63	56.8%	3	2.7%	111
Primary unknown	48	47.5%	49	48.5%	4	4.0%	101
CNS	63	81.8%	9	11.7%	5	6.5%	77

skin	49	67.1%	20	27.4%	4	5.5%	73
Soft tissue system	39	76.5%	10	19.6%	2	3.9%	51
skeletal-bones etc	23	79.3%	4	13.8%	2	6.9%	29
Intrathoracic organs	4	80.0%	0	0.0%	1	20.0%	5
Endocrine glands	3	75.0%	1	25.0%	0	0.0%	4
Peripheral nervous system	1	100.0%	0	0.0%	0	0.0%	1

**Table 6: Numbers (#) and Proportion of Family History with Hereditary Cancers**

Site wise Family History					
site	Family History	%	No Family History	%	Total
Breast	188	29%	424	65%	657
ovary	30	22%	96	72%	134
colon	33	28%	78	66%	118
Prostate	23	21%	81	76%	107

**Table 7: Numbers (#) and Proportion of System Wise & Family History**

System wise Family History							
System	No Family History	%	Family History	%	Un known	%	Total
Head & Neck	718	76.2%	176	18.7%	48	5.1%	942
Digestive Organs	711	75.8%	197	21.0%	30	3.2%	938
Breast	424	64.5%	188	28.6%	44	6.7%	657
Respiratory system	488	78.1%	122	19.5%	14	2.2%	625
Hematological and RE System	431	89.6%	30	6.2%	20	4.2%	481
Gynecological system	292	71.9%	95	23.4%	19	4.7%	406
Male genital organ	97	77.0%	26	20.6%	3	2.4%	126
Urinary tract	87	78.4%	20	18.0%	3	2.7%	111
Primary unknown	84	83.2%	13	12.9%	4	4.0%	101
CNS	53	68.8%	19	24.7%	5	6.5%	77
skin	58	79.5%	11	15.1%	4	5.5%	73
Soft tissue system	40	78.4%	9	17.6%	2	3.9%	51
skeletal-bones etc	21	72.4%	5	17.2%	3	10.3%	29
Intrathoracic organs	3	60.0%	1	20.0%	1	20.0%	5
Endocrine glands	4	100.0%	0	0.0%	0	0.0%	4
Peripheral nervous system	1	100.0%	0	0.0%	0	0.0%	1

## Leading Cancers - irrespective of Sex

Sl. No	Site	#	%
1	BREAST	657	14.2
2	LUNG	625	13.5
3	MOUTH	282	6.1
4	STOMACH	244	5.3
5	RECTUM	215	4.6
6	TONGUE	199	4.3
7	NHL	168	3.6
8	CERVIX	157	3.4
9	OVARY	134	2.9
10	LARYNX	126	2.7

### 1. Breast Cancer

- Total Number (ICD 10: C50) : 657 (14.2%)
- First leading cancer among females
- Peak age group : 45-49 in females
- Histology: Infiltrating Ductal Carcinoma : 87.7% in females
- Method of Diagnosis: Microscopic : 97.6% in females
- Detailed Microscopic diagnosis : Histology of
  - primary: 87.5% in females
  - Broad Treatment group:
    - Treatment only at RI : 50.7% in females
    - Prior & Treatment at RI: 22.3% in females
  - Clinical Extent of Disease Before treatment (Treatment only at RI):
    - Regional:59.0% in females
  - Intention to treat for new patients: Curative: 83.4%
  - Composite Stage : Stage 2: 45.5% in females

**Table 1: Number and Relative Proportion of Breast cancer by five year age group**

Breast				
Age	Male	%	Female	%
15-19	0	0.0%	1	0.2%
20-24	0	0.0%	1	0.2%
25-29	0	0.0%	7	1.1%
30-34	0	0.0%	22	3.4%
35-39	0	0.0%	50	7.6%
40-44	0	0.0%	84	12.8%
45-49	0	0.0%	109	16.6%
50-54	1	50.0%	93	14.2%
55-59	0	0.0%	80	12.2%
60-64	0	0.0%	79	12.1%
65-69	1	50.0%	69	10.5%
70-74	0	0.0%	33	5.0%
>=75	0	0.0%	27	4.1%
Total	2	100%	655	100%

**Table 2 :Number and Relative Proportion of Breast cancer by Broad treatment group**

Broad Treatment Group	Breast				
	Male	%	Female	%	Total
No treatment	0	0.0%	46	7.0%	46
Incomplete/Treatment advised but not accepted	0	0.0%	63	9.6%	63
Prior & Treatment at RI	1	50.0%	146	22.3%	147
Prior Treatment Only	0	0.0%	68	10.4%	68
Treatment only at RI	1	50.0%	332	50.7%	333
Total	2	100.0%	655	100.0%	657

**Table 3 : Number and Relative Proportion of Breast cancer by Clinical extent of disease**

Clinical Extent Before Treatment	Breast				
	Male	%	Female	%	Total
Direct Extension	0	0.0%	30	4.6%	30
Direct Extension with Regional Nodes	1	50.0%	274	41.8%	275
Distant Metastasis	0	0.0%	81	12.4%	81
Localised	1	50.0%	154	23.5%	155
Recurrent	0	0.0%	5	0.8%	5
Regional Nodes	0	0.0%	2	0.3%	2
Too Advanced	0	0.0%	3	0.5%	3
Treated Elsewhere	0	0.0%	106	16.2%	106
Total	2	100%	655	100%	657

**Table 4: Number and Relative Proportion of Breast cancer by Composite stage**

Composite stage	Breast				
	Male	%	Female	%	total
stage1	0	0.0%	37	5.6%	37
stage2	2	100.0%	298	45.5%	300
stage3	0	0.0%	188	28.7%	188
stage4	0	0.0%	102	15.6%	102
unknown	0	0.0%	30	4.6%	30
Total	2	100%	655	100%	657

**Table 5 :Number and Relative Proportion of Breast cancer by intention to treat for new patients**

Intention to treat	Breast				
	Male	%	Female	%	Total
Curative / Radical	0	0.0%	277	83.4%	277
Pallative	1	100.0%	55	16.6%	56
Total	1	100.0%	332	100.0%	333

**Table 6: Number and Relative Proportion of Breast cancer by Detailed Method of Diagnosis**

<b>Breast</b>					
<b>Method of Diagnosis</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Cytology of Metastasis	0	0.0%	3	0.5%	3
Cytology of Primary	0	0.0%	68	10.4%	68
Histology of Primary	2	100.0%	573	87.5%	575
Endoscopy/surgery etc.	0	0.0%	11	1.7%	11
<b>Total</b>	<b>2</b>	<b>100%</b>	<b>655</b>	<b>100%</b>	<b>657</b>

**Table 7: Number and Relative Proportion of Breast cancer by Diagnostic status**

<b>Breast</b>					
<b>Diagnostic status</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	2	100.0%	639	97.6%	641
No registered at RI	0	0.0%	10	1.5%	10
Suspected (Clinically / To rule out Malignancy )	0	0.0%	1	0.2%	1
Suspected (Microscopically / Radiologically)	0	0.0%	5	0.8%	5
<b>Total</b>	<b>2</b>	<b>100%</b>	<b>655</b>	<b>100%</b>	<b>657</b>

**Table 8: Number and Relative Proportion of Breast cancer by Morphology**

<b>Breast</b>					
<b>Morphology.</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Infiltrating Duct Carcinoma	1	50.0%	575	87.8%	576
Carcinoma	0		17	2.6%	17
Lobular Carcinoma	0		16	2.4%	16
others	1	50.0%	11	1.7%	12
Neoplasam Malignant	0		12	1.8%	12
Papillary Carcinoma	0		7	1.1%	7
MusinousAdenoCarcinoma	0		6	0.9%	6
Phylloids Tumor	0		4	0.6%	4
Medullary Carcinoma	0		3	0.5%	3
Pagets Disease	0		1	0.2%	1
Adenocarcinoma	0		1	0.2%	1
Clear Cell Carcinoma	0		1	0.2%	1
Tubular Adenocarcinoma	0		1	0.2%	1
<b>Total</b>	<b>2</b>	<b>100%</b>	<b>655</b>	<b>100%</b>	<b>657</b>

## II. Lung Cancer

- Total Number (ICD 10: C33-34) :625
  - First leading cancer among males
  - Peak age group: 60-64 in males and 65-69 in females
  - Histology: Adeno carcinoma: 29.8% in males and 51.9% in females
  - Method of Diagnosis : Microscopic : 81.2% in males and 92.3% in females
  - Detailed Microscopic diagnosis : Histology of primary: 66.4% in males and 74% in females
- Broad Treatment group:
- Treatment only at RI : 40.7% in males      Treatment only at RI :33.7% in females
  - Clinical Extent of Disease Before treatment(Treatment only at RI):  
Distant metastasis: 55.4% in males  
Distant metastasis : 74.3% in females
  - Intention to treat for new patients: Palliative: 83% in both males and females
  - Composite Stage: Stage 3: 61.6% in males and 76% in females.

**Table 9: Number and Relative Proportion of Lung cancer by five year age group**

Lung				
Age	Male	%	Female	%
30-34	0	0.0%	3	2.9%
35-39	1	0.2%	1	1.0%
40-44	6	1.2%	2	1.9%
45-49	13	2.5%	7	6.7%
50-54	41	7.9%	17	16.3%
55-59	69	13.2%	16	15.4%
60-64	123	23.6%	18	17.3%
65-69	115	22.1%	21	20.2%
70-74	80	15.4%	10	9.6%
>=75	73	14.0%	9	8.7%
Total	521	100%	104	100%

**Table 10: Number and Relative Proportion of Lung cancer by Broad Treatment Groups**

Broad Treatment Group	Lung				
	Male	%	Female	%	Total
No treatment	179	34.4%	39	37.5%	218
Incomplete/Treatment advised but not accepted	81	15.5%	17	16.3%	98
Prior & Treatment at RI	22	4.2%	8	7.7%	30
Prior Treatment Only	27	5.2%	5	4.8%	32
Treatment only at RI	212	40.7%	35	33.7%	247
Total	521	100.0%	104	100.0%	625

**Table 11: Number and Relative proportion of Lung cancer by clinical extent of disease**

<b>Lung</b>					
Clinical Extent Before Treatment	<b>Male</b>	<b>%</b>	Female	<b>%</b>	<b>Total</b>
Direct Extension	13	2.5%	2	1.9%	15
Direct Extension with Regional Nodes	146	28.0%	19	18.3%	165
Distant Metastasis	270	51.8%	72	69.2%	342
Localised	29	5.6%	1	1.0%	30
Others (specify)	5	1.0%	0	0.0%	5
Regional Nodes	1	0.2%	0	0.0%	1
Too Advanced	42	8.1%	7	6.7%	49
Treated Elsewhere	15	2.9%	3	2.9%	18
<b>Total</b>	<b>521</b>	<b>100%</b>	<b>104</b>	<b>100%</b>	<b>625</b>

**Table 12: Number and Relative Proportion of Lung cancer by histology**

<b>Lung</b>					
<b>Morphology.</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Adenocarcinoma	155	29.8%	54	51.9%	209
Neoplasam Malignant	120	23.0%	13	12.5%	133
Squamous Cell Carcinoma	124	23.8%	7	6.7%	131
Small Cell Carcinoma	45	8.6%	9	8.7%	54
Non SmallCell Carcinoma	38	7.3%	9	8.7%	47
others	15	2.9%	3	2.9%	18
Carcinoma	11	2.1%	2	1.9%	13
MusinousAdenoCarcinoma	4	0.8%	1	1.0%	5
AdenoSquamous Cell Carcinoma	1	0.2%	2	1.9%	3
Papillary AdenoCarcinoma	2	0.4%	1	1.0%	3
Large Cell Neuroendocrine Carcinoma	3	0.6%	0		3
Neuroendocrine Carcinoma	2	0.4%	1	1.0%	3
Carcinioid Tumor	0		1	1.0%	1
Mucin SecretingAdenoCarcinoma	0		1	1.0%	1
Squamous Cell Carcinoma Keratinising	1	0.2%	0		1
<b>Total</b>	<b>521</b>	<b>100%</b>	<b>104</b>	<b>100%</b>	<b>625</b>



**Table 13: Number and Relative Proportion of Lung cancer by Intention to treat for new patients**

<b>Lung</b>					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	36	17.0%	5	14.3%	41
Palliative	176	83.0%	29	82.9%	205
Symptomatic	0	0.0%	1	2.9%	1
Total	212	100.0%	35	100.0%	247

**Table 14: Number and Relative Proportion of Lung cancer by Composite stage**

<b>Lung</b>					
Composite stage	Male	%	Female	%	total
stage1	29	5.6%	3	2.9%	32
stage2	145	27.8%	19	18.3%	164
stage3	321	61.6%	79	76.0%	400
stage4	15	2.9%	3	2.9%	18
unknown	11	2.1%	0	0.0%	11
Total	521	100%	104	100%	625

**Table 15: Number and Relative Proportion of Lung cancer by Detailed Method of Diagnosis**

<b>Lung</b>					
Method of Diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	26	5.0%	7	6.7%	33
Cytology of Primary	39	7.5%	10	9.6%	49
Histology of Metastasis	16	3.1%	1	1.0%	17
Histology of Primary	346	66.4%	77	74.0%	423
Endoscopy/surgery etc.	91	17.5%	9	8.7%	100
Ultrasonogram	1	0.2%	0	0.0%	1
X-Ray	2	0.4%	0	0.0%	2
Total	521	100%	104	100%	625

**Table 16: Number and Relative Proportion of Lung cancer by Diagnostic status**

<b>Lung</b>					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	423	81.2%	96	92.3%	519
Suspected (Clinically / To rule out Malignancy )	1	0.2%	0	0.0%	1
Suspected (Microscopically / Radiologically)	97	18.6%	8	7.7%	105
Total	521	100%	104	100%	625

### III. Mouth Cancer

- Total Number (ICD 10: C03-06) : 282
- Peak age group : 60-64 in males and 65-69 in females
- Histology : Squamous cell carcinoma: 87.8 in males and 82.7% in females
- Method of Diagnosis : Microscopic : 98.3% in males and 98.2% in females
- Detailed Microscopic diagnosis: Histology of primary 96.5% in males 94.5% in females
- Broad Treatment group :  
Treatment only at RI : 55.4% in males      Treatment only at RI : 62.7% in females
- Clinical Extent of Disease Before treatment (Treatment only at RI)  
Localised : 23.7%    Regional: 69.1%    Distant : 6.2% in males  
Localised: 30.4%    Regional: 65.2%    Distant : 4.3% in females
- Intention to treat for new patients:  
Radical: 65.6% in males and 47.8% in females
- Composite Stage : Stage 3: 44.8% in males and 43.6% in females

**Table 17: Number and Relative Proportion of Mouth cancer by five year age group**

<b>Mouth</b>				
<b>Age</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>
30-34	4	2.3%	0	0.0%
35-39	5	2.9%	2	1.8%
40-44	11	6.4%	2	1.8%
45-49	16	9.3%	4	3.6%
50-54	11	6.4%	7	6.4%
55-59	18	10.5%	8	7.3%
60-64	30	17.4%	16	14.5%
65-69	29	16.9%	20	18.2%
70-74	24	14.0%	17	15.5%
>=75	24	14.0%	34	30.9%
<b>Total</b>	<b>172</b>	<b>100%</b>	<b>110</b>	<b>100%</b>

**Table 18: Number and Relative Proportion of Mouth cancer by Broad treatment group**

Broad Treatment Group	Mouth				
	Male	%	Female	%	Total
No treatment	11	6.4%	11	10.0%	22
Incomplete/Treatment advised but not accepted	36	20.9%	16	14.5%	52
Prior & Treatment at RI	10	5.8%	6	5.5%	16
Prior Treatment Only	19	11.0%	8	7.3%	27
Treatment only at RI	96	55.8%	69	62.7%	165
Total	172	100.0%	110	100.0%	282

**Table 19: Number and Relative Proportion of Mouth cancer by Clinical Extent of Disease**

Mouth					
Clinical Extent Before Treatment	Male	%	Female	%	Total
Direct Extension	19	11.0%	10	9.1%	29
Direct Extension with Regional Nodes	84	48.8%	48	43.6%	132
Distant Metastasis	4	2.3%	1	0.9%	5
Localised	35	20.3%	30	27.3%	65
Recurrent	6	3.5%	1	0.9%	7
Regional Nodes	0	0.0%	2	1.8%	2
Too Advanced	5	2.9%	4	3.6%	9
Treated Elsewhere	19	11.0%	14	12.7%	33
Total	172	100%	110	100%	282

**Table 20: Number and Relative Proportion of Mouth cancer by Composite stage**

Mouth					
Composite stage	Male	%	Female	%	total
stage1	15	8.7%	7	6.4%	22
stage2	23	13.4%	22	20.0%	45
stage3	77	44.8%	48	43.6%	125
stage4	48	27.9%	27	24.5%	75
unknown	9	5.2%	6	5.5%	15
Total	172	100%	110	100%	282

**Table 21: Number and Relative Proportion of Mouth cancer by intention to treat for new patients**

Mouth					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	63	65.6%	33	47.8%	96
Palliative	33	34.4%	36	52.2%	69
Total	96	100.0%	69	100.0%	165

**Table 22: Number and Relative Proportion of Mouth cancer by Detailed Method of diagnosis**

<b>Mouth</b>					
<b>Method of Diagnosis</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Cytology of Metastasis	1	0.6%	3	2.7%	4
Cytology of Primary	3	1.7%	2	1.8%	5
Histology of Primary	166	96.5%	104	94.5%	270
Endoscopy/surgery etc.	2	1.2%	1	0.9%	3
<b>Total</b>	<b>172</b>	<b>100%</b>	<b>110</b>	<b>100%</b>	<b>282</b>

**Table 23: Number and Relative Proportion of Mouth cancer by Diagnostic status**

<b>Mouth</b>					
<b>Diagnostic status</b>	<b>Male</b>	<b>%</b>	<b>Fe-male</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	169	98.3%	108	98.2%	277
Not registered at RI	2	1.2%	1	0.9%	3
Suspected (Clinically / To rule out Malignancy )	0	0.0%	1	0.9%	1
Suspected (Microscopically / Radiologically)	1	0.6%	0	0.0%	1
<b>Total</b>	<b>172</b>	<b>100%</b>	<b>110</b>	<b>100%</b>	<b>282</b>

**Table 24: Number and Relative Proportion of Mouth cancer by Morphology**

<b>Mouth</b>					
<b>Morphology.</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Squamous Cell Carcinoma	156	90.7%	94	85.4	250
Verrcous Carcinoma	3	1.7%	7	6.4%	10
Carcinoma	4	2.3%	2	1.8%	6
Neoplasam Malignant	3	1.7%	2	1.8%	5
Adenocystic Carcinoma	2	1.2%	2	1.8%	4
MucoepidermoidCarcinona	2	1.2%	1	0.9%	3
Microinvasive Squamous Cell Carcinoma	1	0.6%	1	0.9%	2
Clear Cell Carcinoma	1	0.6%	1	0.9%	2
<b>Total</b>	<b>172</b>	<b>100%</b>	<b>110</b>	<b>100%</b>	<b>282</b>

## IV. Stomach Cancer

- Total Number (ICD 10: C16) : 244
- Peak age group : 60-64, 65-69 in males and 70-74 in females
- Histology : Adeno carcinoma : 63.3% in males 62.5% in females
- Method of Diagnosis : Microscopic: 97.2% in males and 93.8% in females
- Detailed Microscopic diagnosis : Histology of primary: 93.9% in males 93.8% in females
- Broad Treatment group:  
Treatment only at RI : 28.9% in males and 26.6% in females
- Clinical Extent of Disease Before treatment  
Distant metastasis: 35.6% in males and 37.5% in females
- Intention to treat for new patients :
- Palliative: 62.5% in males and 52.9% in females
- Composite Stage : Stage 3: 53.3% in males and 56.3% in females

**Table 25: Number and Relative Proportion of Stomach cancer by Five year age group**

Stomach				
Age	Male	%	Female	%
25-29	0	0.0%	1	1.6%
30-34	2	1.1%	1	1.6%
35-39	1	0.6%	4	6.3%
40-44	5	2.8%	5	7.8%
45-49	11	6.1%	7	10.9%
50-54	14	7.8%	4	6.3%
55-59	25	13.9%	6	9.4%
60-64	37	20.6%	6	9.4%
65-69	37	20.6%	5	7.8%
70-74	26	14.4%	8	12.5%
>=75	22	12.2%	17	26.6%
Total	180	100%	64	100%

**Table 26: Number and Relative Proportion of Stomach cancer by Broad treatment group**

Broad Treatment Group	Stomach				
	Male	%	Female	%	Total
No treatment	48	26.7%	25	39.1%	73
Incomplete/Treatment advised but not accepted	34	18.9%	11	17.2%	45
Prior & Treatment at RI	19	10.6%	7	10.9%	26
Prior Treatment Only	27	15.0%	4	6.3%	31
Treatment only at RI	52	28.9%	17	26.6%	69
Total	180	100.0%	64	100.0%	244

**Table 27: Number and Relative Proportion of Stomach cancer by Clinical extent of disease**

<b>Stomach</b>					
<b>Clinical Extent Before Treatment</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Direct Extension	16	8.9%	1	1.6%	17
Direct Extension with Regional Nodes	37	20.6%	10	15.6%	47
Distant Metastasis	64	35.6%	24	37.5%	88
Localised	20	11.1%	11	17.2%	31
Others (specify)	3	1.7%	1	1.6%	4
Recurrent	4	2.2%	1	1.6%	5
Too Advanced	24	13.3%	11	17.2%	35
Treated Elsewhere	12	6.7%	5	7.8%	17
<b>Total</b>	<b>180</b>	<b>100%</b>	<b>64</b>	<b>100%</b>	<b>244</b>

**Table 28: Number and Relative Proportion of Stomach cancer by Composite stage**

<b>Stomach</b>					
<b>Composite stage</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>total</b>
stage1	16	8.9%	14	21.9%	30
stage2	59	32.8%	12	18.8%	71
stage3	96	53.3%	36	56.3%	132
stage4	1	0.6%	1	1.6%	2
unknown	8	4.4%	1	1.6%	9
<b>Total</b>	<b>180</b>	<b>100%</b>	<b>64</b>	<b>100%</b>	<b>244</b>

**Table 29: Number and Relative Proportion of Stomach cancer by intention to treat for new patients**

<b>Stomach</b>					
<b>Intention to treat</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Curative / Radical	19	36.5%	8	47.1%	27
Palliative	33	63.5%	9	52.9%	42
<b>Total</b>	<b>52</b>	<b>100.0%</b>	<b>17</b>	<b>100.0%</b>	<b>69</b>

**Table 30: Number and Relative Proportion of Stomach cancer by Method of Diagnosis**

<b>Stomach</b>					
<b>Method of Diagnosis</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Cytology of Metastasis	4	2.2%	0	0.0%	4
Endoscopy/surgery etc.	6	3.3%	4	6.3%	10
Histology of Metastasis	1	0.6%	0	0.0%	1
Histology of Primary	169	93.9%	60	93.8%	229
<b>Total</b>	<b>180</b>	<b>100%</b>	<b>64</b>	<b>100%</b>	<b>244</b>

**Table 31: Number and Relative Proportion of Stomach cancer by Diagnostic status**

<b>Stomach</b>					
<b>Diagnostic status</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	175	97.2%	60	93.8%	235
Suspected (Clinically / To rule out Malignancy)	1	0.6%	0	0.0%	1
Suspected (Microscopically / Radiologically)	4	2.2%	4	6.3%	8
<b>Total</b>	<b>180</b>	<b>100%</b>	<b>64</b>	<b>100%</b>	<b>244</b>

**Table 32: Number and Relative Proportion of Stomach cancer by Morphology**

<b>Stomach</b>					
<b>Morphology.</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Adenocarcinoma	114	63.3%	40	62.5%	154
Signet RingCell Carcinoma	23	12.8%	10	15.6%	33
Neoplasam Malignant	8	4.4%	4	6.3%	12
Squamous Cell Carcinoma	8	4.4%	3	4.7%	11
Carcinoma	10	5.6%	1	1.6%	11
Gastrointestinal Stromal Tumor	7	3.9%	2	3.1%	9
Carcinoma Diffuse Type	4	2.2%	1	1.6%	5
others	1	0.6%	3	4.7%	4
Mucin SecretingAdenoCarcinoma	3	1.7%	0		3
Neuroendocrine Carcinoma	1	0.6%	0		1
Adenocarcinoma Intestinal Type	1	0.6%	0		1
<b>Total</b>	<b>180</b>	<b>100%</b>	<b>64</b>	<b>100%</b>	<b>244</b>

## V. Rectum Cancer

- Total Number (ICD 10: C19-20) :215
- Peak age group : 60-64 in males and 65-69 in females
- Histology : Adeno carcinoma : 79.8% in males and 79.1% in females
- Method of Diagnosis : Microscopic : 95.2% in males 94.5% in females
- Detailed Microscopic diagnosis : Histology of Primary: 95.2% in males 93.4% in females.
- Broad Treatment group  
Treatment only at RI : 50.8 % in males and 47.3% in females
- Clinical Extent of Disease Before treatment:  
Direct extension with regional nodes : 31.5% in males and 40.7% in females
- Intention to treat for new patients:  
Radical : 74.6 % in males and 76.7 % in females
- Composite Stage: Stage 2: 47.6% in males and 48.4% in females

**Table 33 : Number and Relative Proportion of Rectum cancer by Five year age group**

Rectum				
Age	Male	%	Female	%
20-24	0	0.0%	1	1.1%
25-29	1	0.8%	1	1.1%
30-34	0	0.0%	4	4.4%
35-39	4	3.2%	4	4.4%
40-44	4	3.2%	4	4.4%
45-49	10	8.1%	8	8.8%
50-54	12	9.7%	7	7.7%
55-59	17	13.7%	11	12.1%
60-64	22	17.7%	15	16.5%
65-69	19	15.3%	17	18.7%
70-74	22	17.7%	7	7.7%
>=75	13	10.5%	12	13.2%
Total	124	100%	91	100%

**Table 34: Number and Relative Proportion of Rectum cancer by Broad treatment group**

Broad Treatment Group	Rectum				
	Male	%	Female	%	Total
No treatment	18	14.5%	11	12.1%	29
Incomplete/Treatment advised but not accepted	12	9.7%	13	14.3%	25
Prior & Treatment at RI	12	9.7%	7	7.7%	19
Prior Treatment Only	19	15.3%	17	18.7%	36
Treatment only at RI	63	50.8%	43	47.3%	106
Total	124	100.0%	91	100.0%	215



**Table 35: Number and Relative Proportion of Rectum cancer by Clinical extent of disease before treatment**

<b>Rectum</b>					
<b>Clinical Extent Before Treatment</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Direct Extension	18	14.5%	9	9.9%	27
Direct Extension with Regional Nodes	39	31.5%	37	40.7%	76
Distant Metastasis	28	22.6%	13	14.3%	41
Localised	22	17.7%	15	16.5%	37
Others (specify)	1	0.8%	3	3.3%	4
Recurrent	2	1.6%	3	3.3%	5
Too Advanced	3	2.4%	4	4.4%	7
Treated Elsewhere	11	8.9%	7	7.7%	18
<b>Total</b>	<b>124</b>	<b>100%</b>	<b>91</b>	<b>100%</b>	<b>215</b>

**Table 36: Number and Relative Proportion of Rectum cancer by Composite stage**

<b>Rectum</b>					
<b>Composite stage</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>total</b>
stage1	22	17.7%	21	23.1%	43
stage2	59	47.6%	44	48.4%	103
stage3	39	31.5%	19	20.9%	58
stage4	2	1.6%	0	0.0%	2
unknown	2	1.6%	7	7.7%	9
<b>Total</b>	<b>124</b>	<b>100%</b>	<b>91</b>	<b>100%</b>	<b>215</b>

**Table 37: Number and Relative Proportion of Rectum cancer by intention to treat for new patients**

<b>Rectum</b>					
<b>Intention to treat</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Curative / Radical	47	74.6%	33	76.7%	80
Pallative	16	25.4%	10	23.3%	26
<b>Total</b>	<b>63</b>	<b>100.0%</b>	<b>43</b>	<b>100.0%</b>	<b>106</b>

**Table 38: Number and Relative Proportion of Rectum cancer by Detailed Method of Diagnosis**

<b>Rectum</b>					
<b>Method of Diagnosis</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Cytology of Primary	1	0.8%	0	0.0%	1
Endoscopy	2	1.6%	1	1.1%	3
Histology of Primary	118	95.2%	85	93.4%	203
Endoscopy/surgery etc.	2	1.6%	5	5.5%	7
Ultrasonogram	1	0.8%	0	0.0%	1
<b>Total</b>	<b>124</b>	<b>100%</b>	<b>91</b>	<b>100%</b>	<b>215</b>

**Table 39: Number and Relative Proportion of Rectum cancer by Diagnostic status**

<b>Rectum</b>					
<b>Diagnostic status</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	118	95.2%	86	94.5%	204
No registered at RI	2	1.6%	0	0.0%	2
Suspected (Clinically / To rule out Malignancy )	2	1.6%	0	0.0%	2
Suspected (Microscopically / Radiologically)	2	1.6%	5	5.5%	7
<b>Total</b>	<b>124</b>	<b>100%</b>	<b>91</b>	<b>100%</b>	<b>215</b>

**Table 40: Number and Relative Proportion of Rectum cancer by Morphology**

<b>Rectum</b>					
<b>Morphology.</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Adenocarcinoma	99	79.8%	72	79.1%	171
Neoplasam Malignant	6	4.8%	6	6.6%	12
Mucin SecretingAdenoCarcinoma	7	5.6%	4	4.4%	11
Carcinoma	6	4.8%	2	2.2%	8
MusinousAdenoCarcinoma	1	0.8%	3	3.3%	4
Squamous Cell Carcinoma	1	0.8%	2	2.2%	3
Signet RingCell Carcinoma	3	2.4%	0		3
Papillary AdenoCarcinoma	0		1	1.1%	1
Neuroendocrine Carcinoma	1	0.8%	0		1
others	0		1	1.1%	1
<b>Total</b>	<b>124</b>	<b>100%</b>	<b>91</b>	<b>100%</b>	<b>215</b>

## VI. Tongue Cancer

- Total Number (ICD 10: C01-02) : 199
- Peak age group : 55-59 in males and 60-64 in females
- Histology : Squamous cell carcinoma: 92.3% in males and 93% in females
- Method of Diagnosis :Microscopic: 97.9% in males and 96.5% in females
- Detailed Microscopic diagnosis : Histology of Primary : 95.1% in males and 96.5% in females
- Broad Treatment group:  
Treatment only at RI : 62.7% in males and 57.9 % in females
- Clinical Extent of Disease Before treatment
- Direct extension with regional nodes: 47.9 % in males and 40.4% in females
- Intention to treat for new patients :  
Radical : 78.7 % in males and 72.7 % in females
- Composite Stage : Stage 4: 33.8% in males stage3: 29.8% in females

**Table 41: Number and Relative Proportion of Tongue cancer by Five year age group**

Tongue				
Age	Male	%	Female	%
30-34	6	4.2%	1	1.8%
35-39	5	3.5%	3	5.3%
40-44	11	7.7%	5	8.8%
45-49	19	13.4%	4	7.0%
50-54	18	12.7%	6	10.5%
55-59	20	14.1%	4	7.0%
60-64	19	13.4%	11	19.3%
65-69	18	12.7%	10	17.5%
70-74	15	10.6%	7	12.3%
>=75	11	7.7%	6	10.5%
Total	142	100%	57	100%

**Table 42: Number and Relative Proportion of Tongue cancer by Broad Treatment Group**

Broad Treatment Group	Tongue				
	Male	%	Female	%	Total
No treatment	7	4.9%	4	7.0%	11
Incomplete/Treatment advised but not accepted	23	16.2%	10	17.5%	33
Prior & Treatment at RI	8	5.6%	6	10.5%	14
Prior Treatment Only	15	10.6%	4	7.0%	19
Treatment only at RI	89	62.7%	33	57.9%	122
Total	142	100.0%	57	100.0%	199

**Table 43: Number and Relative Proportion of Tongue cancer by Clinical extent of disease before treatment**

<b>Tongue</b>					
<b>Clinical Extent Before Treatment</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Direct Extension	13	9.2%	2	3.5%	15
Direct Extension with Regional Nodes	68	47.9%	23	40.4%	91
Distant Metastasis	3	2.1%	1	1.8%	4
Localised	43	30.3%	19	33.3%	62
Not Applicable / Unknown Primary	0	0.0%	1	1.8%	1
Others (specify)	0	0.0%	1	1.8%	1
Recurrent	3	2.1%	2	3.5%	5
Too Advanced	2	1.4%	2	3.5%	4
Treated Elsewhere	10	7.0%	6	10.5%	16
<b>Total</b>	<b>142</b>	<b>100%</b>	<b>57</b>	<b>100%</b>	<b>199</b>

**Table 44: Number and Relative Proportion of Tongue cancer by Composite Stage**

<b>Tongue</b>					
<b>Composite stage</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>total</b>
stage1	25	17.6%	12	21.1%	37
stage2	28	19.7%	10	17.5%	38
stage3	37	26.1%	17	29.8%	54
stage4	48	33.8%	14	24.6%	62
unknown	4	2.8%	4	7.0%	8
<b>Total</b>	<b>142</b>	<b>100%</b>	<b>57</b>	<b>100%</b>	<b>199</b>

**Table 45: Number and Relative Proportion of Tongue cancer by Intention to treat for new patients**

<b>Tongue</b>					
<b>Intention to treat</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Curative / Radical	70	78.7%	24	72.7%	94
Pallative	19	21.3%	9	27.3%	28
<b>Total</b>	<b>89</b>	<b>100.0%</b>	<b>33</b>	<b>100.0%</b>	<b>122</b>

**Table 46: Number and Relative Proportion of Tongue cancer by Detailed Method of Diagnosis**

<b>Tongue</b>					
<b>Method of Diagnosis</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Cytology of Metastasis	1	0.7%	0	0.0%	1
Cytology of Primary	3	2.1%	0	0.0%	3
Endoscopy/surgery etc.	2	1.4%	2	3.5%	4
Histology of Metastasis	1	0.7%	0	0.0%	1
Histology of Primary	135	95.1%	55	96.5%	190
<b>Total</b>	<b>142</b>	<b>100%</b>	<b>57</b>	<b>100%</b>	<b>199</b>

**Table 47: Number and Relative Proportion of Tongue cancer by Diagnostic Status**

<b>Tongue</b>					
<b>Diagnostic status</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	139	97.9%	55	96.5%	194
No registered at RI	1	0.7%	1	1.8%	2
Suspected (Clinically / To rule out Malignancy )	1	0.7%	1	1.8%	2
Suspected (Microscopically / Radiologically)	1	0.7%	0	0.0%	1
<b>Total</b>	<b>142</b>	<b>100%</b>	<b>57</b>	<b>100%</b>	<b>199</b>

**Table 48: Number and Relative Proportion of Tongue cancer by Morphology**

<b>Tongue</b>					
<b>Morphology.</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Squamous Cell Carcinoma	131	92.3%	53	93.0%	184
Neoplasam Malignant	4	2.8%	2	3.5%	6
Microinvasive Squamous Cell Carcinoma	3	2.1%	0		3
Carcinoma	1	0.7%	1	1.8%	2
Verrcous Carcinoma	2	1.4%	0		2
MucoepidermoidCarcinona	1	0.7%	0		1
Adenocystic Carcinoma	0		1	1.8%	1
<b>Total</b>	<b>142</b>	<b>100%</b>	<b>57</b>	<b>100%</b>	<b>199</b>

## VII. NHL

- Total Number (ICD 10: C82-85) : 168
- Peak age group : 60-64 in males and females
- Histology : Large B cell Diffuse : 44.2% in males and 51.6% in females
- Method of Diagnosis : Microscopic: 98.1% in males and 96.7% in females
- Detailed Microscopic diagnosis: Histology of primary: 91.3% in males and 89.1% in females
- Broad Treatment group:  
Treatment only at RI : 38.5% % in males and 43.8% in females
- Clinical Extent of Disease Before treatment:  
Regional nodes: 47.1% in males and 48.4% in females
- Intention to treat for new patients :  
Radical : 45% in males and 42.9% in females
- Composite Stage : stage 4: 30.8% in males and 31.3% in females

**Table 49: Number and Relative Proportion of NHL cancer by Five year age group**

NHL				
Age	Male	%	Female	%
0-4	1	1.0%	0	0.0%
10-14	2	1.9%	0	0.0%
15-19	1	1.0%	0	0.0%
25-29	4	3.8%	1	1.6%
30-34	2	1.9%	2	3.1%
35-39	3	2.9%	5	7.8%
40-44	6	5.8%	2	3.1%
45-49	6	5.8%	5	7.8%
50-54	10	9.6%	9	14.1%
55-59	11	10.6%	8	12.5%
60-64	17	16.3%	11	17.2%
65-69	16	15.4%	9	14.1%
70-74	11	10.6%	7	10.9%
>=75	14	13.5%	5	7.8%
Total	104	100%	64	100%

**Table 50: Number and Relative Proportion of NHL cancer by Broad treatment group**

Broad Treatment Group	NHL				
	Male	%	Female	%	Total
No treatment	28	26.9%	16	25.0%	44
Incomplete/Treatment advised but not accepted	17	16.3%	10	15.6%	27
Prior & Treatment at RI	6	5.8%	2	3.1%	8
Prior Treatment Only	13	12.5%	8	12.5%	21
Treatment only at RI	40	38.5%	28	43.8%	68
Total	104	100.0%	64	100.0%	168

**Table 51: Number and Relative Proportion of NHL cancer by Clinical extent of disease before treatment**

NHL					
Clinical Extent Before Treatment	Male	%	Female	%	Total
Direct Extension	6	5.8%	6	9.38%	12
Direct Extension with Regional Nodes	3	2.9%	4	6.25%	7
Distant Metastasis	2	1.9%	1	1.56%	3
Localised	9	8.7%	3	4.69%	12
Not Applicable / Unknown Primary	16	15.4%	7	10.94%	23
Not Palpable	4	3.8%	2	3.13%	6
Recurrent	3	2.9%	2	3.13%	5
Regional Nodes	49	47.1%	31	48.44%	80
Too Advanced	4	3.8%	2	3.13%	6
Treated Elsewhere	8	7.7%	6	9.38%	14
Total	104	100%	64	100	168

**Table 52: Number and Relative Proportion of NHL cancer by Composite stage**

NHL					
Composite stage	Male	%	Female	%	total
stage1	10	9.6%	6	9.4%	16
stage2	12	11.5%	11	17.2%	23
stage3	18	17.3%	12	18.8%	30
stage4	32	30.8%	20	31.3%	52
unknown	32	30.8%	15	23.4%	47
Total	104	100%	64	100%	168

**Table 53: Number and Relative Proportion of NHL cancer by intention to treat for new patients**

NHL					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	18	45.0%	12	42.9%	30
Pallative	21	52.5%	16	57.1%	37
Symptomatic	1	2.5%	0	0.0%	1
Total	40	100.0%	28	100.0%	68

**Table 54: Number and Relative Proportion of NHL cancer by Detailed Method of diagnosis**

NHL					
Method of Diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	2	1.9%	0	0.0%	2
Cytology of Primary	6	5.8%	5	7.8%	11
Histology of Metastasis	0	0.0%	1	1.6%	1
Histology of Primary	95	91.3%	57	89.1%	152
Endoscopy/surgery etc.	1	1.0%	1	1.6%	2
Total	104	100%	64	100%	168

**Table 55: Number and Relative Proportion of NHL cancer by Diagnostic status**

NHL					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	102	98.1%	62	96.9%	164
No registered at RI	0	0.0%	1	1.6%	1
Suspected (Microscopically / Radiologically)	2	1.9%	1	1.6%	3
Total	104	100%	64	100%	168

**Table 56: Number and Relative Proportion of NHL cancer by Morphology**

NHL					
Morphology.	Male	%	Female	%	Total
NHL, Large B Cell Diffuse	46	44.2%	33	51.6%	79
NHL Nos	16	15.4%	6	9.4%	22
NHL, Follicular Lymphoma	10	9.6%	11	17.2%	21
Mature T-Cell Lymphoma	8	7.7%	3	4.7%	11
NHL, Small B Lymphocytic	4	3.8%	3	4.7%	7



others	5	4.8%	2	3.1%	7
Malignant Lymphoma	4	3.8%	2	3.1%	6
NHL,Mantle Cell Lymphoma	3	2.9%	2	3.1%	5
Anaplastic Large Cell Lymphoma T-Cell and Null Cell Type	2	1.9%	1	1.6%	3
Cutaneous T-Cell Lymphoma	3	2.9%	0		3
NHL,Marginal Zone B Cell lymphoma	2	1.9%	0		2
Angioimmunoblastic T-Cell Lymphoma	1	1.0%	0		1
Precursor Cell Lymphoblastic Lymphoma	0		1	1.6%	1
<b>Total</b>	<b>104</b>	<b>100%</b>	<b>64</b>	<b>100%</b>	<b>168</b>

## VIII. Cervix

- Total Number (ICD 10: C53) : 157
- Peak age group : 60-64
- Histology : Squamous cell carcinoma non keratinizing : 41.4%
- Method of Diagnosis : Microscopic: 96.2%
- Detailed Microscopic diagnosis : Histology of primary: 97.5%
- Broad Treatment group : Treatment only at RI: 63.1%
- Clinical Extent of Disease Before treatment:  
Direct extension: 36.9%
- Intention to treat for new patients  
Radical : 76.8 %
- Composite Stage : Stage 3: 33.1%

**Table 57: Number and Relative Proportion of Cervix cancer by Five year age group**

Cervix Uteri		
Age	Female	%
20-24	1	0.6%
30-34	1	0.6%
35-39	3	1.9%
40-44	14	8.9%
45-49	13	8.3%
50-54	23	14.6%
55-59	25	15.9%
60-64	27	17.2%
65-69	24	15.3%
70-74	15	9.6%
>=75	11	7.0%
Total	157	100%

**Table 58: Number and Relative Proportion of Cervix cancer by Broad Treatment Group**

<b>Broad Treatment Group</b>	<b>Cervix Uteri</b>		
	<b>Female</b>	<b>%</b>	<b>Total</b>
No treatment	10	6.4%	10
Incomplete/Treatment advised but not accepted	25	15.9%	25
Prior & Treatment at RI	13	8.3%	13
Prior Treatment Only	10	6.4%	10
Treatment only at RI	99	63.1%	99
<b>Total</b>	<b>157</b>	<b>100.0%</b>	<b>157</b>

**Table 59: Number and Relative Proportion of Cervix cancer by Clinical extent of disease before treatment**

<b>Cervix Uteri</b>			
<b>Clinical Extent Before Treatment</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Direct Extension	58	36.9%	58
Direct Extension with Regional Nodes	11	7.0%	11
Distant Metastasis	12	7.6%	12
Localised	47	29.9%	47
Not Applicable / Unknown Primary	1	0.6%	1
Recurrent	4	2.5%	4
Too Advanced	13	8.3%	13
Treated Elsewhere	11	7.0%	11
<b>Total</b>	<b>157</b>	<b>100%</b>	<b>157</b>

**Table 60: Number and Relative Proportion of Cervix cancer by Composite Stage**

<b>Cervix Uteri</b>			
<b>Composite stage</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
stage1	33	21.0%	33
stage2	51	32.5%	51
stage3	52	33.1%	52
stage4	17	10.8%	17
unknown	4	2.5%	4
<b>Total</b>	<b>157</b>	<b>100%</b>	<b>157</b>

**Table 61: Number and Relative Proportion of Cervix cancer by intention to treat for new patients**

<b>Cervix Uteri</b>			
<b>Intention to treat</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Curative / Radical	76	76.8%	76
Pallative	23	23.2%	23
Total	99	100.0%	99

**Table62: Number and Relative Proportion of Cervix cancer by Detailed Method of Diagnosis**

<b>Cervix Uteri</b>			
<b>Method of Diagnosis</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Histology of Primary	153	97.5%	153
Endoscopy/surgery etc.	4	2.5%	4
Total	157	100%	157

**Table 63: Number and Relative Proportion of Cervix cancer by Diagnostic status**

<b>Cervix Uteri</b>			
<b>Diagnostic status</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	151	96.2%	151
No registered at RI	2	1.3%	2
Suspected (Microscopically / Radiologically)	4	2.5%	4
Total	157	100%	157

**Table 64: Number and Relative Proportion of Cervix cancer by Morphology**

<b>Cervix Uteri</b>		
<b>Morphology.</b>	<b>#</b>	<b>%</b>
Squamous Cell Carcinoma Non Keratinising	65	41.4%
Squamous Cell Carcinoma	37	23.6%
Squamous Cell Carcinoma Keratinising	22	14.0%
Adenocarcinoma	9	5.7%
Endocervical Adenocarcinoma	5	3.2%
Carcinoma	4	2.5%
Neoplasam Malignant	4	2.5%
others	4	2.5%
Entometroid Carcinoma	3	1.9%
AdenoSquamous Cell Carcinoma	2	1.3%
MusinousAdenoCarcinoma	1	0.6%
Clear Cell Carcinoma	1	0.6%
<b>Total</b>	<b>157</b>	<b>100%</b>

## IX. Ovary

- Total Number (ICD 10: C56) : 134
- Peak age group : 50-54
- Histology : Serous Cyst adenocarcinoma : 34.3%
- Method of Diagnosis : Microscopic : 85.8%
- Detailed Microscopic diagnosis : Histology of primary : 64.2%
- Broad Treatment group : Treatment only at RI: 34.3%
- Clinical Extent of Disease Before treatment  
Distant Metastasis: 43.3%
- Intention to treat for new patients  
Radical : 71.7 %
- Composite Stage : Stage 3: 35.8%

**Table 65: Number and Relative Proportion of Ovary cancer by Five year age group**

Ovary		
Age	Female	%
15-19	1	0.7%
20-24	1	0.7%
25-29	1	0.7%
30-34	2	1.5%
35-39	9	6.7%
40-44	12	9.0%
45-49	15	11.2%
50-54	23	17.2%
55-59	15	11.2%
60-64	19	14.2%
65-69	16	11.9%
70-74	12	9.0%
>=75	8	6.0%
Total	134	100%

**Table 66: Number and Relative Proportion of Ovary cancer by Broad treatment group**

Broad Treatment Group	Ovary		
	Female	%	Total
No treatment	26	19.4%	26
Incomplete/Treatment advised but not accepted	15	11.2%	15
Prior & Treatment at RI	28	20.9%	28
Prior Treatment Only	19	14.2%	19
Treatment only at RI	46	34.3%	46
Total	134	100.0%	134

**Table 67: Number and Relative Proportion of Ovary cancer by Clinical extent of disease before treatment**

Ovary			
Clinical Extent Before Treatment	Female	%	Total
Direct Extension	11	8.2%	11
Direct Extension with Regional Nodes	5	3.7%	5
Distant Metastasis	58	43.3%	58
Localised	23	17.2%	23
Others (specify)	2	1.5%	2
Recurrent	9	6.7%	9
Too Advanced	9	6.7%	9
Treated Elsewhere	17	12.7%	17
Total	134	100.0%	134

**Table 68: Number and Relative Proportion of Ovary cancer by composite stage**

Ovary			
Composite stage	Female	%	total
stage1	19	14.2%	19
stage2	4	3.0%	4
stage3	48	35.8%	48
stage4	45	33.6%	45
unknown	18	13.4%	18
Total	134	100.0%	134

**Table 69: Number and Relative Proportion of Ovary cancer by intention to treat for new patients**

Ovary			
Intention to treat	Female	%	Total
Curative / Radical	33	71.7%	33
Pallative	13	28.3%	13
Total	46	100.0%	46

**Table 70: Number and Relative Proportion of Ovary cancer by Detailed Method of diagnosis**

<b>Ovary</b>			
<b>Method of Diagnosis</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Cytology of Metastasis	12	9.0%	12
Cytology of Primary	11	8.2%	11
Endoscopy/surgery etc.	17	12.7%	17
Histology of Metastasis	5	3.7%	5
Histology of Primary	86	64.2%	86
Specific Biochemical and/or immunological Tests	2	1.5%	2
Ultrasonogram	1	0.7%	1
<b>Total</b>	<b>134</b>	<b>100%</b>	<b>134</b>

**Table 71: Number and Relative Proportion of Ovary cancer by Diagnostic status**

<b>Ovary</b>			
<b>Diagnostic status</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	115	85.8%	115
No registered at RI	2	1.5%	2
Suspected (Microscopically / Radiologically)	17	12.7%	17
<b>Total</b>	<b>134</b>	<b>100%</b>	<b>134</b>

**Table 72: Number and Relative Proportion of Ovary cancer by Morphology**

<b>Ovary</b>		
<b>Morphology.</b>	<b>Female</b>	<b>%</b>
Serous CystadenoCarcinoma	46	34.3%
Neoplasam Malignant	30	22.4%
Adenocarcinoma	19	14.2%
Carcinoma	8	6.0%
MusinousAdenoCarcinoma	7	5.2%
Entometroid Carcinoma	4	3.0%
others	3	2.2%
Papillary Serous CystadennoCarcinoma	3	2.2%
Squamous Cell Carcinoma	2	1.5%
Mucinous CystadenoCarcinoma	2	1.5%
Granulosa Cell Tumor	2	1.5%
Papillary AdenoCarcinoma	2	1.5%
Squamous Cell Carcinoma Non Keratinising	2	1.5%
Papillary Carcinoma	1	0.7%
Dysgerminoma	1	0.7%
Clear Cell Carcinoma	1	0.7%
Cystadeno Carcinoma	1	0.7%
<b>Total</b>	<b>134</b>	<b>100%</b>

## X. Larynx

- Total Number (ICD 10: C32) : 126
- Peak age group : 60-64 in males and females
- Histology : Squamous cell carcinoma: 83.3% in males and 60% in females
- Method of Diagnosis : Microscopic : 95.9% in males and 100% in females
- Detailed Microscopic diagnosis : Histology of primary : 91.7% in males and 80% in females
- Broad Treatment group:  
Treatment only at RI : 58.7 % in males and 60 % in females
- Clinical Extent of Disease Before treatment  
Localised: 40.5% in males and 40% in females
- Intention to treat for new patients  
Radical : 76.1% in males and 66.7% in females
- Composite Stage : stage 3: 36.4% in males and stage 1: 40 % in males

**Table 73 : Number and Relative Proportion of Larynx cancer by Five year age group**

Larynx				
Age	Male	%	Female	%
40-44	3	2.5%	0	0.0%
45-49	6	5.0%	0	0.0%
50-54	12	9.9%	1	20.0%
55-59	25	20.7%	0	0.0%
60-64	29	24.0%	2	40.0%
65-69	16	13.2%	0	0.0%
70-74	13	10.7%	1	20.0%
>=75	17	14.0%	1	20.0%
Total	121	100%	5	100%

**Table 74: Number and Relative Proportion of Larynx cancer by Broad treatment group**

Broad Treatment Group	Larynx				
	Male	%	Female	%	Total
No treatment	8	6.6%	1	20.0%	9
Incomplete/Treatment advised but not accepted	17	14.0%	1	20.0%	18
Prior & Treatment at RI	15	12.4%	0	0.0%	15
Prior Treatment Only	10	8.3%	0	0.0%	10
Treatment only at RI	71	58.7%	3	60.0%	74
Total	121	100.0%	5	100.0%	126

**Table 75: Number and Relative Proportion of Larynx cancer by Clinical extent disease before treatment**

<b>Larynx</b>					
<b>Clinical Extent Before Treatment</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Direct Extension	19	15.7%	0	0.0%	19
Direct Extension with Regional Nodes	31	25.6%	3	60.0%	34
Distant Metastasis	4	3.3%	0	0.0%	4
Localised	49	40.5%	2	40.0%	51
Others (specify)	1	0.8%	0	0.0%	1
Recurrent	5	4.1%	0	0.0%	5
Regional Nodes	1	0.8%	0	0.0%	1
Too Advanced	2	1.7%	0	0.0%	2
Treated Elsewhere	9	7.4%	0	0.0%	9
<b>Total</b>	<b>121</b>	<b>100%</b>	<b>5</b>	<b>100%</b>	<b>126</b>

**Table 76: Number and Relative Proportion of Larynx cancer by intention to treat for new patients**

<b>Larynx</b>					
<b>Intention to treat</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Curative / Radical	54	76.1%	2	66.7%	56
Pallative	17	23.9%	1	33.3%	18
<b>Total</b>	<b>71</b>	<b>100.0%</b>	<b>3</b>	<b>100.0%</b>	<b>74</b>

**Table 77: Number and Relative Proportion of Larynx cancer by composite stage**

<b>Larynx</b>					
<b>Composite stage</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>total</b>
stage1	33	27.3%	2	40.0%	35
stage2	15	12.4%	0	0.0%	15
stage3	44	36.4%	0	0.0%	44
stage4	23	19.0%	2	40.0%	25
unknown	6	5.0%	1	20.0%	7
<b>Total</b>	<b>121</b>	<b>100%</b>	<b>5</b>	<b>100%</b>	<b>126</b>



**Table 78: Number and Relative Proportion of Larynx cancer by Detailed Method of diagnosis**

<b>Larynx</b>					
<b>Method of Diagnosis</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Cytology of Metastasis	3	2.5%	1	20.0%	4
Cytology of Primary	3	2.5%	0	0.0%	3
Histology of Metastasis	1	0.8%	0	0.0%	1
Histology of Primary	111	91.7%	4	80.0%	115
Endoscopy/surgery etc.	3	2.5%	0	0.0%	3
<b>Total</b>	<b>121</b>	<b>100%</b>	<b>5</b>	<b>100%</b>	<b>126</b>

**Table 79: Number and Relative Proportion of Larynx cancer by Diagnostic status**

<b>Larynx</b>					
<b>Diagnostic status</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Microscopically Confirmed	116	95.9%	5	100.0%	121
No registered at RI	1	0.8%	0	0.0%	1
Suspected (Clinically / To rule out Malignancy )	1	0.8%	0	0.0%	1
Suspected (Microscopically / Radiologically)	3	2.5%	0	0.0%	3
<b>Total</b>	<b>121</b>	<b>100%</b>	<b>5</b>	<b>100%</b>	<b>126</b>

**Table 80: Number and Relative Proportion of Larynx cancer by Morphology**

<b>Larynx</b>					
<b>Morphology.</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>
Squamous Cell Carcinoma	102	84.3%	3	60.0%	105
Neoplasam Malignant	8	6.6%	1	20.0%	9
Carcinoma	3	2.5%	0		3
others	2	1.7%	1	20.0%	3
Squamous Cell Carcinoma Non Keratinising	2	1.7%	0		2
Squamous Cell Carcinoma Keratinising	2	1.7%	0		2
Sarcomatiod Carcinoma	1	0.8%	0		1
MucoepidermoidCarcinona	1	0.8%	0		1
<b>Total</b>	<b>121</b>	<b>100%</b>	<b>5</b>	<b>100%</b>	<b>126</b>

## **ABBREVIATION**

ICD – International Classification of Disease ICMR- Indian Council of Medical Research

HBCR – Hospital Based Cancer Registry

NCRP - National Cancer Registry Program

NHL - Non Hodgkin Lymphoma

RI – Reporting Institution

S - Surgery

C - Chemotherapy

R - Radiation

TRC - Tobacco Related Cancers

## **REFERENCES:**

1. Isabel dos Santos Silva (1999), Cancer Epidemiology, Principles and Methods IARC Publications, France.
2. Maclennan et al (1978) Cancer Registration and its Techniques IARC Scientific Publications No.21 France.
3. Young J.L (1991) Hospital Based Cancer Registry in Cancer Registration Principles and Methods IARC Publications France.
4. April Fritz, Constance Percy et al. International Classification of Disease for Oncology Third Edition, World Health Organization Geneva 2000.
5. John L. Young, Steven D. Roffers et al, seer summary staging manual 2000 codes and coding instruction



Published by  
**Malabar Cancer Centre**  
(An autonomous centre under Government of Kerala)  
Thalassery-670 103, Phone : (+91) 0490 2355881, Fax: 0490 2355880  
Website: [www.mcc.kerala.gov.in](http://www.mcc.kerala.gov.in)